Prevention and control of infections with hepatitis viruses in correctional settings by Lyerla, Harold Craig et al.
Morbidity and Mortality Weekly Report
Recommendations and Reports January 24, 2003 / Vol. 52 / No. RR-1
Centers for Disease Control and Prevention
SAFER   •   HEALTHIER   •   PEOPLETM
INSIDE: Continuing Education Examination
Prevention and Control of Infections with Hepatitis
Viruses in Correctional Settings
MMWR
SUGGESTED CITATION
Centers for Disease Control and Prevention.
Prevention and control of infections with hepatitis
viruses in correctional settings. MMWR 2003;
52(No. RR-1):[inclusive page numbers].
The MMWR series of publications is published by the
Epidemiology Program Office, Centers for Disease
Control and Prevention (CDC), U.S. Department of
Health and Human Services, Atlanta, GA 30333.
Centers for Disease Control and Prevention
Julie L. Gerberding, M.D., M.P.H.
Director
David W. Fleming, M.D.
Deputy Director for Science and Public Health
Dixie E. Snider, Jr., M.D., M.P.H.
Associate Director for Science
Epidemiology Program Office
Stephen B. Thacker, M.D., M.Sc.
Director
Office of Scientific and Health Communications
John W. Ward, M.D.
Director
Editor, MMWR Series
Suzanne M. Hewitt, M.P.A.
Managing Editor











Correctional Populations ...................................................... 2
Health Care in the Correctional System ............................... 3
Risk Factors for Viral Hepatitis Transmission Among
Incarcerated Persons ........................................................ 3
Epidemiology and Outcome of Infection
with Hepatitis Viruses ....................................................... 4
Preventing and Controlling Viral Hepatitis ........................... 7
Rationale for Prevention and Control of Viral Hepatitis
in Correctional Settings .................................................. 16
Rating the Recommendations ............................................. 17
Recommendations for Juvenile Correctional
Facilities — Hepatitis A Virus Infection ............................ 17
Recommendations for Juvenile Correctional
Facilities — Hepatitis B Virus Infection ............................ 18
Recommendations for Juvenile Correctional
Facilities — Hepatitis C Virus Infection ............................ 20
Juvenile Health Education and Release Planning................ 21
Recommendations for Adult Correctional
Facilities — Hepatitis A Virus Infection ............................ 22
Recommendations for Adult Correctional
Facilities — Hepatitis B Virus Infection ............................ 22
Recommendations for Adult Correctional
Facilities — Hepatitis C Virus Infection ............................ 24
Adult Health Education and Release Planning .................... 25
Preventing and Controlling Hepatitis Virus Infections
Among Correctional Staff ............................................... 26
Implementation of Recommendations ................................ 27
Internet Resources ............................................................. 28
Published Resources .......................................................... 28
References ......................................................................... 28
Appendix ........................................................................... 34
The preparers of this report have signed a conflict of interest
disclosure form that verifies no conflict of interest.
Vol. 52 / RR-1 Recommendations and Reports 1
The material in this report originated in the National Center for
Infectious Diseases, James M. Hughes, M.D., Director, and the Division
of Viral Hepatitis, Harold S. Margolis, M.D., Director.





Harold S. Margolis, M.D.
Division of Viral Hepatitis
National Center for Infectious Diseases
Summary
This report consolidates previous recommendations and adds new ones for preventing and controlling infections with hepatitis
viruses in correctional settings. These recommendations provide guidelines for juvenile and adult correctional systems regarding 1)
identification and investigation of acute viral hepatitis; 2) preexposure and postexposure immunization for hepatitis A and
hepatitis B; 3) prevention of hepatitis C virus infection and its consequences; 4) health education; and 5) release planning.
Implementation of these recommendations can reduce transmission of infections with hepatitis viruses among adults at risk in both
correctional facilities and the outside community. These recommendations were developed after consultation with other federal
agencies and specialists in the fields of corrections, correctional health care, and public health at a meeting in Atlanta, March 5–
7, 2001. This report can serve as a resource for those involved in planning and implementing health-care programs for incarcer-
ated persons.
Introduction
Persons incarcerated in correctional systems comprise
approximately 0.7% of the U.S. population and have a dis-
proportionately greater burden of infectious diseases, includ-
ing infections with hepatitis viruses and other infections of
public health importance (e.g., human immunodeficiency
virus [HIV], sexually transmitted disease [STD], and tuber-
culosis [TB] infections) (1). In 2000, >8 million inmates of
prisons and jails were released and returned to the community
(A. Beck, Ph.D., Bureau of Justice Statistics, personal com-
munication, 2002). Recent estimates indicate 12%–39% of
all Americans with chronic hepatitis B virus (HBV) or hepati-
tis C virus (HCV) infections were releasees during the previ-
ous year (1) (Table 1).
The significance of including incarcerated populations in
community-based disease prevention and control strategies is
now recognized by public health and correctional profession-
als (2,3). Improved access to medical care and prevention ser-
vices for incarcerated populations can benefit communities
by reducing disease transmission and medical costs (4–8).
Inmates who participate in health-related programs while
incarcerated have lower recidivism rates and are more likely to
maintain health-conscious behaviors (4). Finally, because
incarcerated persons have a high frequency of infection with
hepatitis viruses, community efforts to prevent and control
these infections require inclusion of the correctional popula-
tion (9–11). However, implementation of preventive health
programs for incarcerated persons has substantial challenges.
Correctional staff are among groups at potential risk for
occupationally acquired infections with bloodborne pathogens.
Therefore, recommendations are also reviewed for prevention
and control of infections with hepatitis viruses among correc-
tional workers.
Definitions
 Adolescent: Person aged >10 and <19 years.
Adult: Person aged >19 years.
Anti-HAV: Total antibody to hepatitis A virus (HAV)
detected in serum of persons with acute or resolved HAV
infection; indicates a protective immune response to infec-
tion, vaccination, and passively acquired antibody.
Anti-HBc: Antibody to hepatitis B core antigen; positive test
indicates past or current infection with HBV.
Anti-HBs: Antibody to hepatitis B surface antigen; indicates
immunity to HBV infection, either from HBV infection or
immunization.
Anti-HCV: Antibody to HCV; positive test indicates past
or current infection with HCV.
Arrestee: Person placed under arrest by law enforcement who
has not been formally charged with a crime.
Body fluids, potentially infectious: Semen, vaginal secretions,
cerebrospinal fluid, synovial fluid, pleural fluid, pericardial
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Source: Adapted from National Commission on Correctional Health Care. The health status of soon-to-be-released inmates: a report to Congress.
Chicago, IL: National Commission on Correctional Health Care, 2002. Available at http://www.ncchc.org/pubs_stbr.html.
* Based on 1.7 million inmates in prisons and jails, 1997 (15).
† Based on estimated 7.75 million unduplicated released inmates (2); A. Beck, Ph.D. Bureau of Justice Statistics, personal communication, 2002.
§ (31,83,84,85,86,88,89,90,92,94).
¶ Data from CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey (NHANES III), adjusted to include persons of
Asian origin (76).
** (88,121,122); L. Wang, Ph.D., New York State Department of Health, personal communication, 2001; D. Lau, M.D., University of Texas Medical Branch—
Galveston, personal communication, 2001.
†† Based on data from NHANES III (107).
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fluid, peritoneal fluid, and amniotic fluid. Potentially infec-
tious body fluids include any body fluid visibly contaminated
with blood, and all body fluids in situations where identifying
blood contamination is difficult or impossible.
Detainee: Person arrested and legally charged with a crime
who is held in a correctional facility before trial.
HAV: Hepatitis A virus, the infectious agent that causes HAV
infection and hepatitis A.
HBIG: Hepatitis B immune globulin; sterile preparation of
high-titer antibodies (immunoglobulins) to hepatitis B sur-
face antigen obtained from pooled human plasma of immu-
nized persons and which provides protection against HBV
infection.
HBeAg: Hepatitis B e antigen; positive test correlates with
HBV replication and infectivity.
HBsAg: Hepatitis B surface antigen; positive test indicates
an active HBV infection.
HBV: Hepatitis B virus, the infectious agent that causes HBV
infection, hepatitis B, and chronic liver disease.
HBV DNA: Deoxyribonucleic acid from HBV; positive test
indicates active infection.
HCC: Hepatocellular carcinoma; a primary liver cancer
caused by chronic HBV or HCV infection that is usually
fatal.
HCV: Hepatitis C virus, the infectious agent that causes
HCV infection, hepatitis C, and chronic liver disease.
HCV RNA: Ribonucleic acid from HCV; positive test indi-
cates active infection.
HDV: Hepatitis D virus, a viroid (incomplete virus) that
requires an active (acute or chronic) HBV infection to repli-
cate and cause delta hepatitis virus infection, delta hepatitis,
and chronic liver disease.
IDUs: Injection-drug users; persons who have ever used
needles to inject illicit drugs.
IgM anti-HAV: Immunoglobulin M antibody to HAV; posi-
tive test indicates acute HAV infection.
IgM anti-HBc: Immunoglobulin M antibody to hepatitis B
core antigen; positive test indicates acute HBV infection.
IG: Immune globulin; sterile preparation of antibodies
(immunoglobulins) made from pooled human plasma that
contains anti-HAV and provides protection against hepatitis A.
Infant: Person aged <1 year.
Inmate: Incarcerated person.
Jail: Locally operated correctional facility that confines per-
sons pending arraignment, awaiting trial and sentencing, or
serving their sentences (usually <1 year).
Juvenile: Person aged <19 years, in custody of the legal sys-
tem.
Prison: Adult correctional facility under the jurisdiction of
state or federal authorities that confines persons with a sen-
tence of >1 year.
Seroconversion: The change of a serologic test from negative
to positive.




 In 1997, approximately 12% of persons aged 16 years
reported at least one arrest in their lifetimes (12). In 1999, a
reported 108,965 juvenile offenders were held in residential
placement facilities (13). In 1994, the average length of stay
in public facilities for juvenile releasees was 2 weeks for those
detained and 5 months for those committed; the stay in pri-
vate facilities (primarily a committed population) averaged 3.5
months (12). Of arrested juveniles not incarcerated, the
majority are diverted to alternative programs (e.g., teen courts
or restorative justice) where they remain under supervision of
the juvenile justice system. Approximately 74% of incarcer-
ated juvenile offenders are held in public facilities, and the
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population, especially in jails, and the suboptimal funding of
correctional health and prevention services, often limits the
correctional system in providing both curative and preventive
care.
Infectious diseases — including acquired immune deficiency
syndrome (AIDS), STDs, TB, and viral hepatitis — are more
prevalent among correctional inmates than the general popu-
lation. In 1997, an estimated 46,000–76,000 prison and jail
inmates had serologic evidence of syphilis; 8,900 had AIDS
(4% of the U.S. AIDS burden); and 1,400 had active TB (4%
of the U.S. TB burden) (1).
Among incarcerated persons, shared risk factors (e.g., injec-
tion-drug use) can result in populations coinfected with HBV,
HCV, or HIV. Coinfections can make treatment of chronic
viral hepatitis, AIDS, and TB more difficult because of the
need to use multiple drugs, which increases the chance of hepa-
totoxicity and other adverse events. In addition, both TB
chemoprophylaxis and HIV postexposure prophylaxis can be
complicated by the presence of chronic liver disease (24,25).
Risk Factors
for Viral Hepatitis Transmission
Among Incarcerated Persons
Drug Use
 During 1990–1999, the rate of arrest for substance abuse
violations among persons aged 10–17 years increased by 132%
(12,26). Injection-drug use is reported by 3.3%–6% of incar-
cerated juveniles (A. Thomas, M.D., Oregon Health Divi-
sion; and R. Bair, M.D., Bexar County Juvenile Detention
Center, San Antonio, Texas; personal communications, 2001).
Among juvenile detainees, 53% of males and 38% of females
tested positive for marijuana use at the time of arrest, <17%
tested positive for cocaine, and <18% were positive for meth-
amphetamine (27).
Arrested adults also have a high prevalence of illicit drug
use. In 2000, 21% of state prisoners and 59% of federal pris-
oners were incarcerated for drug offenses (13). In 1997
inmate surveys, 83% of state prisoners and 73% of federal
prisoners reported past drug use, and 57% of state prisoners
and 45% of federal prisoners reported using drugs in the month
before their offense (28). Among jail inmates, drug use in the
month before incarceration was reported by 55%, and injec-
tion-drug use was reported by 18% (29). However, urine test-
ing at entry has indicated drug use might be substantially
underreported by jail inmates (30). Injection-drug use during
incarceration has been reported by 3%–28% of adult
inmates (31–34). Although certain correctional systems
rest in facilities operated by private contractors (14). Adult
jails hold >7,600 juveniles, and approximately 3,100 are held
in adult prisons (15). Females account for 27% of juveniles
arrested and 13% of those in residential placement (14,16).
Of juveniles arrested in 1999, approximately 72% were white,
25% black, and 3% of other races. However, a disproportion-
ate number of racial and ethnic minorities were detained in
residential placement (40% black and 18% Hispanic).
Adults
 At the end of 2001, adult jail and prison populations
totaled 1.96 million — a 71% increase from 1990 (13). Prior
incarceration as juveniles was reported by 9% of adults in fed-
eral prisons and by 20% in state prisons (17). According to
2000 data, racial/ethnic minorities were overrepresented, with
46% black, 36% white, 16% Hispanic, and 2% other races.
Approximately 6.6% of adult inmates are female, a 111%
increase since 1990; of incoming women to state prisons, 5%
are pregnant (18). Among adult U.S. residents, 1 in every 112
men and 1 in every 1,724 women were sentenced to state or
federal prisons in 2001 (13).
The estimated 12.6 million admissions and 12.6 million
releases from local jails, and 625,000 admissions and 606,000
releases from prisons represent annual turnover rates of 1300%
and 40%, respectively (1,15; A. Beck, Ph.D., Bureau of Jus-
tice Statistics, personal communication, 2002).
Staff
 In 2000, >457,000 custody and security officers worked in
the U.S. correctional system, including both public and pri-
vate sectors (19). These officers comprise approximately two
thirds of all correctional staff, which also includes professional,
technical, educational, clerical, maintenance, food service, and
administrative workers (20,21).
Health Care
in the Correctional System
 Upon incarceration, all adults and the majority of juveniles
lose access to the usual public and private health-care and dis-
ease-prevention services. Their health care becomes the sole
responsibility of either the correctional system (federal, tribal,
state, or local), or less frequently, the public health system (22).
For the majority of persons, entry into the correctional system
provides an opportunity to access health care. In one series,
approximately 78% of newly incarcerated females had abnor-
mal Papanicolaou smears, and >50% had vaginal infections
or STDs (23). However, the rapid turnover of the incarcerated
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offer substance-abuse treatment and education programs,
demand usually exceeds program capacity (20). There appear
to be no comprehensive risk-reduction programs available
within correctional facilities.
Sexual Behavior
 All states have laws prohibiting sex between adult residents
of correctional systems (35). Despite these laws, 2%–30% of
inmates have sex while incarcerated (31,36–38). Outbreaks of
syphilis and hepatitis B among inmates reflect sexual activity
in correctional facilities (31,33,39,40). Although two state
prison systems and five city or county correctional systems
make condoms available to adult inmates and detainees for
use in their facilities (Vermont, Mississippi, New York City,
Philadelphia, San Francisco, Washington D.C., Los Angeles),
no juvenile correctional systems are known to provide condoms
(E. Dunlap, National Juvenile Detention Association, personal
communication, 2001).
Percutaneous Exposures of Uncertain
Risk
 Percutaneous exposures have the potential to transfer
infectious blood and transmit bloodborne pathogens. Tattoos
and other percutaneous exposures (e.g., bites and abrasions)
are common in correctional facilities and have the potential
to expose residents and correctional staff to blood and body
fluids (34,41,42). Case-control studies indicate tattooing is
not a risk factor for acquiring acute hepatitis B or hepatitis C
(43,44). However, results from seroprevalence studies of
noninstitutionalized populations have been variable, and stud-
ies of highly select groups might not be generalizable to other
populations (45). One study of a limited number of IDUs
suggested an increased risk for both HBV and HCV infection
among those tattooed while in prison (46), but limited stud-
ies of both adult and juvenile inmate populations have not
confirmed this finding (33; R. Bair, M.D., Bexar County
Juvenile Detention Center, San Antonio, Texas, personal com-
munication, 2001).
Occupational Exposures
 Correctional employees have reported injuries from human
bites, needles, and other sharp instruments, as well as skin and
mucous membrane exposures to blood and body fluids (41,42).
Occupational transmission of HBV infection among hospi-
tal-based workers has been linked to percutaneous and
mucous membrane exposures, and HBV infection has been
primarily associated with percutaneous exposure. Transmis-
sions of HBV and HCV infections have not been associated
with intact skin exposures (10,47). Limited data from correc-
tional workers have indicated 21% reported blood contact with
intact skin, and 7% reported a percutaneous exposure (includ-
ing needle stick, cut with a contaminated object, or bite) or
mucus membrane exposure (48).
Epidemiology and Outcome
of Infection with Hepatitis Viruses
Hepatitis A Virus Infection
HAV infection is usually acquired by the fecal-oral route,
produces a self-limited disease that does not result in chronic
infection or long-term liver disease, and usually produces symp-
toms of acute viral hepatitis among adolescents and adults
after an average incubation period of 28 days (range: 15–50
days). Signs and symptoms usually last <2 months, although
10%–15% of symptomatic persons have prolonged or relaps-
ing disease lasting <6 months (49). Peak infectivity occurs
during the 2-week period before the onset of jaundice or
elevation of liver enzymes, when the concentration of virus in
stool is highest (11). Persons with chronic liver disease who
acquire hepatitis A are at increased risk for fulminant hepatitis (50).
Epidemiology of HAV Infection
 In the United States, the majority of cases of hepatitis A
occur through person-to-person transmission during
communitywide outbreaks (11,51). Viral transmission can
occur through close personal contact (e.g., household con-
tact, sexual contact, drug use, or children playing), and con-
taminated food or water (e.g., infected food-handlers or raw
shellfish). The most frequently reported source of infection
(12%–26%) is household or sexual contact with a person with
HAV infection; however, 45%–50% of patients have no iden-
tified source for their infection (51,52). Historically, the highest
rates of disease have occurred in 11 western U.S. states and
certain counties, which accounted for approximately 50% of
cases during 1987–1997 (11,52).
HAV infection is common among IDUs. Injection-drug use
has been reported by 5%–19% of hepatitis A patients. In cer-
tain communities, hepatitis A outbreaks involving users of
injected and noninjected methamphetamine have accounted
for approximately 30% of reported cases (11,51,53,54). Cross-
sectional serologic surveys demonstrate that users of illicit drugs
have a higher prevalence of infection than the general U.S.
population (11,55). Viremia occurs during HAV infection,
and transmission has occurred from parenteral blood expo-
sure (e.g., blood transfusion or injection-drug use) on occa-
sion (56). However, the majority of transmissions among users
of illicit drugs are believed to occur through fecal contamination
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of drug paraphernalia and subsequent percutaneous inocula-
tion, as well as from close personal contact (57).
Hepatitis A outbreaks among men who have sex with men
(MSM) are frequently reported, and cyclic outbreaks occur in
urban areas of the United States (58,59). HAV-infected MSM
report more frequent oral-anal contact, longer duration of
sexual activity, and a larger number of sex partners than per-
sons without serologic evidence of infection (60–63).
HAV Infection in Correctional Settings
 No hepatitis A outbreaks have been reported from correc-
tional settings, although a substantial proportion of incarcer-
ated persons have risk factors for infection (e.g., drug use or
MSM). The prevalence of prior HAV infection among incar-
cerated persons is estimated at 22%–39%, which is similar to
age-adjusted prevalence rates in the general U.S. population
(11; C. Shapiro, M.D., CDC, personal communication, 2002;
T. Lincoln, M.D., Hampden County Correctional Center,
Ludlow, Massachusetts; and D. Lau, M.D., University of Texas
Medical Branch—Galveston; personal communications,
2001). Employment in a correctional setting has not been iden-
tified as a risk factor for HAV infection.
Hepatitis B Virus Infection
HBV is a bloodborne pathogen, transmitted by percutane-
ous or permucosal (e.g., sexual) exposure to infectious blood
or body fluids (e.g., semen or saliva). HBV circulates in high
titers in the blood and lower titers in other body fluids (e.g.,
semen, vaginal fluid, or saliva), and is approximately 100 times
more infectious than HIV and 10 times more infectious than
HCV (47).
Acute hepatitis B develops in approximately 30%–50% of
adults at the time of initial infection and is characterized by
anorexia, nausea, vomiting, and often jaundice. The risk of
progression to chronic infection varies with age, being highest
among young children and infants (30%–90%) and lowest
among adolescents and adults (2%–6%) (64).
The majority of persons with chronic HBV infection are
asymptomatic, and one third have no evidence of liver dis-
ease, despite high levels of viral replication in hepatocytes (65).
The remainder have chronic hepatitis (mild, moderate, or
severe) that can lead to cirrhosis and HCC. Persons with
chronic HBV infection have a 15%–25% lifetime risk of death
from chronic liver disease or HCC (66–70). Rates of progres-
sion to cirrhosis and HCC vary according to age at acquisi-
tion of chronic infection; HBeAg status; coinfection with
HDV, HIV, HCV; and alcohol abuse (69,71–75). HBV-
related liver disease and HCC cause approximately 3,000
deaths in the United States annually (S. Goldstein, M.D.,
CDC, unpublished data, 2002).
Epidemiology of HBV Infection
An estimated 5% of the civilian, noninstitutionalized U.S.
population has serologic evidence of past or present HBV
infection, and 0.4%–0.5% have chronic infection and serve
as the primary source of infection for others (9,76). Overall
prevalence of HBV infection differs among racial/ethnic popu-
lations and is highest among persons who have immigrated
from areas with a high endemicity of HBV infection (e.g.,
Asia, Pacific Islands, Africa, and the Middle East) (77). Preva-
lence of infection among blacks is four times prevalence among
whites (11.9% compared with 2.6%) (76).
During 1987–1998, reported cases of acute hepatitis B
declined by 76% (8). Nonetheless, an estimated 78,000 per-
sons were infected with HBV in 2001 (G. Armstrong, M.D.,
CDC, unpublished data, 2002). Disease incidence is highest
among blacks, followed by Hispanics and whites, and highest
among persons aged 25–39 years (8,52). The age of newly
infected persons has increased from a median of 27 years dur-
ing 1982–1988 to 32 years during 1994–1998, probably as a
result of vaccination of adolescents and young adults and
changes in high-risk behaviors in certain populations (8).
Before national prevention programs began in 1990, perinatal
and early childhood transmission accounted for 30% of
chronic HBV infections (78).
Sex is the predominant mode of HBV transmission among
adults and adolescents, accounting for more than half of newly
acquired infections (8). Among reported cases of acute hepa-
titis B, approximately 40% reported heterosexual exposure to
an infected partner or multiple partners, and 15% were MSM.
In addition, 14% of persons with acute hepatitis B reported
injection-drug use. Thirty-three percent of persons with acute
hepatitis B cannot identify a risk factor for infection, although
approximately 50% of those persons have a history of known
risk factors (8).
HBV Infection in Correctional Settings
Juveniles. The majority of juvenile offenders have behav-
iors that place them at risk for HBV infection (e.g., injection-
drug use or unprotected sex with multiple partners). The
prevalence of past HBV infection among noninstitutionalized
high-risk juveniles (e.g., homeless, drug-using, or HIV-
positive) ranges from 3.6% to 19% (79–81) (B.M. Beech,
Ph.D, University of Memphis, Tennessee, 2002), compared
with the <3% prevalence of infection among adolescents in
the general population (76,82). Among incarcerated juveniles,
prevalence of past HBV infection ranges from 0% to 6%
(79,82; A. Thomas, M.D., Oregon Health Division; and R.
Bair, M.D., Bexar County Juvenile Detention Center, San
Antonio, Texas; personal communications, 2001). HBV
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transmission has not been observed in juvenile correctional
settings.
Adults. The prevalence of serologic markers for current or
past HBV infection among prison inmates ranges from 13%
to 47%, and varies by region. Prevalence is higher among
women (37%–47%) than men (13%–32%) (31,83–88)
(T. Lincoln, M.D., Hampden County Correctional Center,
Ludlow, Massachusetts, 2001). Chronic HBV infection is
diagnosed in 1.0%–3.7% of prison inmates, 2–6 times the
national prevalence estimate of 0.5% (31,83,86,88–94), and
comparable to rates of chronic infection among IDUs (5%–
10%) (95–98), and among MSM (1.5%–6%) (99;
D. MacKellar, CDC, personal communication, 2002).
Upon release, susceptible inmates are often at increased risk
for infection because they resume high-risk behaviors. A study
of recidivist women reported an HBV seroconversion rate of
12.2/100 person-years between incarcerations (100), compared
with an estimated incidence of 0.03/100 person-years for the
U.S. population (G. Armstrong, CDC, personal communica-
tion, 2002).
The majority of HBV infections among incarcerated per-
sons are acquired in the community. However, infection is
also transmitted within correctional settings, and incidence
rates have ranged from 0.82% to 3.8%/year (31,34,84). After
identification of a single case of acute hepatitis B in a state
prison, serologic testing identified acute HBV infection in
1.2% of the population (33,34). Highest rate of acute infec-
tion (8%) was determined in the dormitory of the index case
and was associated with sex with another inmate. No other
risk factors were associated with infection. Acute infections
were also identified in other prison dormitories, and chronic
HBV infection was identified in 1% of the inmate popula-
tion. Serologic testing of susceptible inmates 1 year later iden-
tified an additional 3.8% who had become newly infected
with HBV.
Among patients with acute hepatitis B reported to CDC’s
Sentinel Counties Study of Viral Hepatitis, 5.6% have a his-
tory of incarceration during the disease incubation period (8).
HBV transmission in the prison setting can occur through
sexual activity, injection-drug use, and percutaneous exposures
that are not apparent, as it does in households where persons
with chronic HBV infection reside (101,102).
Data are lacking regarding the prevalence of HBV infection
among short- and long-term residents of jails. However, the
demographic and risk factor profiles of jail and prison inmates
are similar, and the burden of HBV infection and risk of trans-
mission might be expected to be similar, especially among long-
term jail residents (13,15,28,29).
Correctional Staff. The overall prevalence of HBV infec-
tion was 12.6% in the only study performed among correc-
tional workers, a rate not significantly different from that of
the general population after adjusting for age and race (48).
Percutaneous and mucous membrane exposures to blood were
relatively infrequent, and the most frequently reported expo-
sure was blood on the skin, which was not associated with
HBV infection.
Hepatitis C Virus Infection
HCV, a bloodborne pathogen, is most efficiently transmit-
ted by direct percutaneous exposure to infectious blood. Of
persons newly infected with HCV, only 20%–30% have symp-
toms of acute hepatitis (10,103,104). Chronic infection
develops among 75%–85% of persons infected as older adults
(aged >45 years) and among 50%–60% of persons infected as
juveniles or young adults (105).
The majority of persons with chronic HCV infection are
asymptomatic, and approximately 30% have no evidence of
liver disease. Among chronically infected persons, biochemi-
cal evidence of chronic liver disease develops among 70% of
those infected as adults, but (on the basis of limited data) in
only 10% of those infected as juveniles (105). The risk for
progression to cirrhosis also varies by age at infection, from
10%–20% among persons infected as older adults to <5%
among persons infected as juveniles or younger adults. In
addition to age, clinical progression is also accelerated by al-
cohol intake, chronic coinfection with HBV, and male sex
(105). Coinfection with HIV increases HCV viral loads, the
rate of progression to fibrosis and cirrhosis, and liver-related
mortality (106). HCC develops among 1%–5% of persons
with chronic hepatitis C.
Epidemiology of HCV Infection
An estimated 3.9 million persons (1.8%) in the civilian,
noninstitutionalized U.S. population have been infected with
HCV, of whom approximately 2.7 million (1.3%) are chroni-
cally infected. In 1990, approximately two thirds of persons
infected with HCV were aged 30–49 years (107). Blacks had
a higher prevalence of HCV infection than whites (3.2% com-
pared with 1.5%), and among black males aged 40–49 years,
prevalence was 9.8% (107).
The highest prevalence of HCV infection (70%–90%) is
reported among those persons with substantial or repeated
direct percutaneous exposures to blood (e.g., IDUs, persons
with hemophilia treated with clotting factor concentrates that
did not undergo viral inactivation, and recipients of transfu-
sions from HCV-positive donors). Moderate infection preva-
lence (10%) has been reported among long-term hemodialysis
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patients, and lower prevalence is reported among persons with
high-risk sexual practices (5%) and health-care workers (1%–
2%) (10). HCV is not transmitted efficiently through occu-
pational exposure. The risk of acquiring HCV infection from
a contaminated needle stick is <2%, and transmission rarely
has been documented from mucous membrane or nonintact
skin exposures (47).
The highest incidence of acute hepatitis C is among per-
sons aged 20–39 years (108,109). Blacks and whites have a
similar incidence of acute disease, and incidence rates are higher
among males than females. Although the incidence of acute
hepatitis C has declined by >80% since 1989, primarily as a
result of a decrease in cases among IDUs, the major risk factor
for HCV infection remains injection-drug use, which accounts
for 60% of newly acquired cases (10,110,111). No associa-
tion has been determined between newly acquired HCV
infection and military service, medical, surgical, or dental pro-
cedures, tattooing, acupuncture, ear piercing, or foreign travel
(43,44). If transmissions from such exposures do occur, the
frequency has been too low to detect.
Although the number of cases of acute hepatitis C among
IDUs has declined dramatically since 1989, both the incidence
and prevalence of HCV infection remain high among this
group (98,112,113). Among IDUs, HCV is transmitted
through the transfer of infected blood by sharing syringes,
needles, or other drug paraphernalia contaminated with the
blood of an infected person (114–116). HCV infection is
acquired more rapidly after the initiation of injection-drug
use than either HBV or HIV infection, and the rate of HCV
infection among juvenile IDUs is four times greater than the
rate of HIV infection. In 1980s studies, approximately 80%
of newly initiated IDUs were infected with HCV within 2
years (98,117,118). This rapid acquisition of HCV infection
was probably caused by the high prevalence of chronic HCV
infection among IDUs, resulting in a greater likelihood of
exposure to an HCV-infected person through sharing of drug
paraphernalia. More recent studies report the rate of HCV
acquisition has slowed, and only one third of IDUs are
infected within 2 years after initiating injection-drug use.
Nonetheless, incidence remains high at 10%–15%/year
(112,116,119,120).
HCV Infection in Correctional Settings
Juveniles. The prevalence of HCV antibody among detained
or incarcerated juveniles is estimated at 2%–3.5%. A history
of injection-drug use is the predominant risk behavior, and
regardless of reported risk behaviors, the prevalence is higher
among females than among males (3%–7% versus 2%–3%)
(A. Thomas, M.D., Oregon Health Division; and R. Bair,
M.D., Bexar County Juvenile Detention Center, San Antonio,
Texas; personal communications, 2001). The extent to which
HCV infection is transmitted within juvenile correctional in-
stitutions is not known.
Adults. Among prison inmates, 16%–41% have serologic
evidence of HCV infection, and 12%–35% have chronic HCV
infection; rates vary by geographic region (88,107,121,122;
L. Wang, Ph.D., New York State Department of Health; D.
Lau, M.D., University of Texas Medical Branch—Galveston;
personal communications, 2001). HCV infection is prima-
rily associated with a history of injection-drug use. In a Wis-
consin study of 1,148 inmates, among the 310 (27%) with a
history of injection-drug use and serologic evidence of HBV
infection or biochemical evidence of liver disease, 91% were
determined to be anti-HCV–positive (J. Pfister, M.S., Wis-
consin State Laboratory of Hygiene, personal communication,
2001). Among HCV-positive entering jail inmates in Massa-
chusetts, 85% reported needle-sharing, prior drug use, or a
history of hepatitis (T. Lincoln, M.D., Hampden County
Correctional Center, Ludlow, Massachusetts, personal com-
munication, 2001).
The risk of HCV acquisition during incarceration is not
well-established. The only published study to examine the
incidence of HCV infection among prison inmates reported a
rate of 1.1 infections/100 person-years of incarceration among
males (121).
Correctional Staff. No published studies have reported the
prevalence of HCV infection among correctional staff. In one
unpublished study, among correctional health-care workers the
prevalence of HCV infection was 2% (R. Gershon, Dr.P.H.,
Columbia University, New York, personal communication,
2002) — no higher than in the general population. This find-
ing is similar to that of studies among other occupational
groups, including hospital-based health-care workers, surgeons,
and public safety workers (10,123).
Preventing and Controlling
Viral Hepatitis
Primary prevention of infection with hepatitis viruses can
be achieved either through immunization (i.e., HAV or HBV)
or through behavioral interventions to reduce risk factors for
infection (i.e., HCV). In addition, identification of persons
with chronic HBV and HCV infection provides an opportu-
nity to initiate activities (e.g., counseling, treatment, or vacci-
nation) that can prevent further disease transmission and reduce
the progression of chronic liver disease. This section summa-
rizes current information and practices to prevent infection
with hepatitis viruses, including immunization, antiviral treat-
ment, and risk-reduction counseling.
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BOX 1. Groups for whom hepatitis A vaccination is
recommended
Persons at Increased Risk for Infection
• Travelers to countries with high endemicity for hepa-
titis A virus infection;
• Men who have sex with men;
• Users of injection and noninjection illegal drugs;
• Persons who receive blood product replacement therapy
for clotting factor disorders; or
• Children and adolescents living in states with histori-
cally elevated rates of hepatitis A.*
Persons at Increased Risk for Adverse
Consequences of Hepatitis A
• Persons with chronic liver disease of any etiology.
Source: CDC. Prevention of hepatitis A through active or passive
immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 1999;48(RR-12):1-37.
* Routine vaccination recommended: Alaska, Arizona, California, Idaho,
Nevada, New Mexico, Oklahoma, Oregon, South Dakota, Utah,  and
Washington; routine vaccination should be considered: Arkansas,
Colorado, Missouri, Montana, Texas, and Wyoming.
Prevention of HAV Infection
Strategy To Prevent HAV Infection
Preexposure Immunization. Vaccination is the most
effective means to prevent HAV infection and reduce disease
incidence. In the United States, preexposure vaccination is rec-
ommended for persons at highest risk for infection and per-
sons for whom infection would result in adverse consequences
(Box 1). In addition, routine vaccination is recommended for
persons aged 2–19 years living in states and communities with
the highest historic rates of disease (11) because conditions
that contribute to communitywide transmission continue to
exist.
Postexposure Prophylaxis. Passive immunization with
immune globulin IG is >85% effective in preventing hepatitis
A after exposure of an unvaccinated person to an infected per-
son, if administered <2 weeks after exposure (11). Anti-HAV
testing is not recommended because it would delay IG ad-
ministration and is likely not cost-effective. Although limited
data indicate hepatitis A vaccine might provide protection
when administered soon after exposure, this has not been evalu-
ated in controlled clinical trials, and use of hepatitis A vaccine
alone is not recommended for postexposure prophylaxis. How-
ever, persons who receive IG postexposure prophylaxis, and
for whom hepatitis A vaccine is also recommended, require
vaccination (11).
Detection and Management of Acute HAV
Infection
The diagnosis of hepatitis A is based on a positive serologic
test for IgM anti-HAV in a person with clinical signs or symp-
toms of acute viral hepatitis. Serologic confirmation of HAV
infection is required because hepatitis A cannot be distin-
guished from other forms of viral hepatitis on the basis of
clinical presentation alone (Box 2). Although management of
clinical illness is supportive, progression to acute liver failure
can occur (especially in persons with chronic liver disease),
and 10%–15% of patients have relapsing illness.
Contact Tracing. Cases of acute hepatitis A are reported to
the appropriate public health authorities, and a contact inves-
tigation is initiated by correctional officials to identify per-
sons who would benefit from postexposure prophylaxis.
Cellmates, sexual contacts, and persons having ongoing close
personal contact with the index case are administered IG
(Box 3) (11).
Current Practices: Prevention of HAV
in Correctional Settings
Nationally, the extent to which juvenile correctional sys-
tems vaccinate against hepatitis A is unknown. A recent
assessment determined that in six of the 17 states where rou-
tine childhood vaccination is recommended, vaccination was
also being conducted in juvenile detention facilities (CDC,
unpublished data, 2002). A limited number of adult correc-
tional systems routinely offer hepatitis A vaccination to all
persons at risk for infection, whereas others offer vaccination
only to inmates infected with HCV.
Prevention of HBV Infection
Strategy To Prevent HBV Infection
Prevention of acute and chronic HBV infection and elimi-
nation of HBV transmission in all age groups is most effec-
tively achieved through hepatitis B vaccination (9). The
national strategy to eliminate HBV transmission has four com-
ponents: 1) prevention of perinatal HBV infection through
maternal screening and postexposure prophylaxis of newborns
of HBsAg-positive mothers; 2) hepatitis B vaccination of all
infants to prevent infection in childhood and at later ages;
3) vaccination of all adolescents not previously vaccinated to
prevent infection in this age group and at later ages; and
4) vaccination of adults and adolescents in groups at increased
risk for infection (Box 4) (9,124).
Hepatitis B vaccination has been included in routine health-
care visits for adolescents, but not for adults at risk for infec-
tion (9,125). Although the majority of persons aged <19 years
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* The Vaccines for Children (VFC) Program was established in 1994 for federal
purchase of vaccine to be administered by a qualified health provider to juveniles
aged <19 years who are American Indian or Alaska Native, uninsured or
underinsured, or on Medicaid. VFC supports purchase of hepatitis A and
hepatitis B vaccines, and HBIG. The VFC website is available at http://
www.cdc.gov/nip/vfc/Default.htm.
BOX 2. Diagnostic testing for infection with hepatitis viruses*
For persons with acute hepatitis, testing should
be performed to differentiate among types of viral
hepatitis.
Acute Hepatitis A
• Immunoglobulin M antibody to hepatitis A virus
(IgM anti-HAV)-positive.
Acute Hepatitis B
• IgM antibody to hepatitis B core antigen (IgM anti-
HBc)-positive; and
• Hepatitis B surface antigen (HBsAg)-positive.
Acute Hepatitis C
• Serum alanine aminotransferase (ALT) levels >7 times
the upper limit of normal;
and
• Antibody to hepatitis C virus (anti-HCV) positive
(repeat reactive) by screening immunoassary, and con-
firmed by a more specific assay (e.g., recombinant
immunoblot assay [RIBA®] for anti-HCV or nucleic
acid testing for HCV RNA);
or
• Anti-HCV–positive (repeat reactive) by screening
immunoassay and a signal-to-cutoff ratio predictive
of a true positive as determined for the particular assay
(e.g., >3.8 for screening enzyme immunoassay [EIA]).
Laboratory tests for diagnosis of chronic hepatitis:
Chronic HBV Infection
• HBsAg-positive, total anti-HBc–positive, and IgM
anti-HBc-negative, or
• HBsAg-positive two times >6 months apart.
Chronic HCV Infection
• Anti-HCV–positive (as defined above) and HCV
RNA-positive >6 months apart.
* See Table 2 for interpretations of other markers of HBV infections.
BOX 3. Contact investigation and postexposure prophylaxis
after identification of a case of hepatitis A
• Contact investigation should be coordinated with
local and state health departments. If the index
patient is a food handler, public health officials should
be directly involved in the investigation to evaluate
the risk for transmission and the need for postexposure
prophylaxis.
• The following persons, if not previously vaccinated,
should be considered candidates for postexposure pro-
phylaxis if exposed to an index patient with hepatitis
A during the two weeks before onset of symptoms. A
single dose of immune globulin (IG) (0.02 mL/kg body
weight, intramuscular) should be administered as soon
as possible (but not >2 weeks after the last exposure)
to
— cellmates or dormitory mates,
— sex contacts,
— other close contacts based on epidemiologic
investigation, or
— other food handlers if the index patient was a food
handler.
• IG is not routinely indicated when an index case
occurs in a school, work setting, or temporary hous-
ing unit.
• When a person with hepatitis A is admitted to a hos-
pital, standard and contact precautions are indicated.
Staff members are at low risk for infection and
postexposure prophylaxis is not indicated.
Source: CDC. Guidelines for viral hepatitis surveillance and case
management. Atlanta, GA: 2002. Available at http://www.cdc.gov/ncidod/
diseases/hepatitis/resource/PDFs/revised%20GUIDELINES%20
formatted4.pdf
not covered by private insurance are covered under the Vac-
cines for Children Program,* similar coverage does not exist
for adults, and cost reimbursement is a substantial barrier to
vaccination of adults (126).
Approximately 56% of persons with hepatitis B have either
been treated for an STD (36%) or incarcerated (29%), factors
for which routine hepatitis B vaccination is recommended
(8,127).
Identification of persons with chronic HBV infection
through diagnostic testing can reduce risks for chronic liver
disease and further transmission of infection; appropriate
medical management and antiviral therapy can reduce risks
for cirrhosis and HCC. Additional morbidity from other
hepatic insults can be reduced through hepatitis A vaccina-
tion, alcohol-reduction counseling, and risk-reduction edu-
cation. The high rate of HBV infection during sex and close
contact (including with cellmates) can be prevented through
vaccination.
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Box 4. Groups recommended for preexposure hepatitis B
vaccination
Universal
• All infants, and
• All children and adolescents not previously vaccinated.
On the Basis of Risk
• Inmates of long-term correctional facilities;
• Injection-drug users;
• Sexually active men who have sex with men;
• Men and women with >1 partner in the previous 6
months, a history of a sexually transmitted disease
(STD), or treatment in an STD clinic;
• Household contacts (including cellmates) and sex part-
ners of persons with chronic HBV infection;
• Persons in occupational groups with exposure to blood
or body fluids;
• Hemodialysis patients;
• Recipients of clotting factor concentrates;
• Long-term international travelers; and
• Clients and staff of institutions for the developmen-
tally disabled.
Sources: CDC. Hepatitis B virus: a comprehensive strategy for
eliminating transmission in the United States through universal childhood
vaccination—recommendations of the Immunization Practices Advisory
Committee (ACIP). MMWR 1991;40(No. RR-13):1–25. CDC. General
recommendations on immunization—recommendations of the Advisory
Committee on Immunization Practices (ACIP) and the American
Academy of Family Physicians (AAFP). MMWR 2002;51(No. RR-2):1–
36. CDC. Recommendations for preventing transmission of infections
among chronic hemodialysis patients. MMWR 2001;50(No. RR-5):1–
43. CDC. Immunization of health-care workers—recommendations of
the Advisory Committee on Immunization Practices (ACIP) and the
Hospital Infection Control Practices Advisory Committee (HICPAC).
MMWR 1997;46(No. RR-18):1–42.
Prevention of Perinatal HBV Infection. Perinatal HBV
infections can be prevented through routine testing to iden-
tify pregnant women who test positive for HBsAg and through
timely postexposure immunization (prophylaxis) of their
infants (78,128,129). Independent of maternal HBsAg sta-
tus, hepatitis B vaccination is recommended for all infants
soon after birth and before their release from the hospital (130).
Initiating hepatitis B vaccination soon after birth serves as a
safety net to prevent HBV infection in infants whose mothers
were not tested (131).
Adolescent Vaccination. Universal vaccination of infants
against hepatitis B was first recommended in the United States
in 1991 (9) and catch-up vaccination of all adolescents was
recommended in 1995 to achieve elimination of HBV trans-
mission in a more timely manner (132–135). Hepatitis B vac-
cination is now required by 33 states for entry to middle school
or seventh grade. Three states have laws that require vaccina-
tion for college entry, and certain colleges require hepatitis B
vaccination for matriculation (136; S. Ainsworth, American
College Health Association, personal communication, 2002).
Juvenile correctional vaccination programs have been estab-
lished to prevent infections among detained persons at high
risk for infection who might not be reached by school require-
ments. Completion of the vaccination series in these programs
has been complicated by population turnover and the need
for parental consent in certain jurisdictions. However, recidi-
vism can bring opportunities to offer inmates second and third
vaccine doses (137; G. Shostak, M.P.H., Massachusetts
Department of Youth Services, personal communication,
2001).
Adult Vaccination. Routine vaccination of infants, young
children and adolescents is expected to eventually eliminate
transmission of HBV among adults in the United States. How-
ever, decades will pass before vaccinated children become pro-
tected adults, and vaccination of adults at increased risk for
infection remains essential to reducing their high incidence of
disease.
Vaccination coverage among adults at occupational risk for
HBV infection has successfully reduced infection incidence
by >90% (138). This was achieved by requiring employers to
provide education and hepatitis B vaccination at no cost to
employees (139). However, early efforts to vaccinate other
adults had limited success, primarily because of a lack of sus-
tained programs and coverage for vaccine cost. More recently,
demonstration programs funded by state and local health
departments to deliver hepatitis B vaccine in correctional fa-
cilities, and STD and substance-abuse–treatment centers, have
demonstrated high vaccination coverage can be achieved
(140,141).
Previously, a major barrier to vaccination of adults at high
risk was the practice of offering vaccine only to persons likely
to complete the series. Although administration of the com-
plete vaccine series should be the goal of any immunization
program, high first-dose and modest second-dose vaccination
coverage rates have been achieved when vaccine is offered to
all persons in settings that serve populations at high risk (140).
Protective levels of antibody develop after 1 dose of hepatitis
B vaccine among 30%–50% and after 2 doses of vaccine among
75% of healthy young adults (142–144).
The transient nature of adult populations in correctional
facilities often prevents completion of the full hepatitis B vac-
cine series. Ensuring follow-up with subsequent doses requires
that an immunization record is included in the medical record
of all inmates, is transferred among correctional facilities, and
is provided to the inmate as part of release planning.
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BOX 5. Method to determine cost-effectiveness of
prevaccination screening for hepatitis B vaccination*
The breakeven point for the cost of prevaccination
serologic testing, when first vaccine dose is administered
at the time of blood draw, is
T = P1 x [P2 + P2(P3)] x v
where
T = cost of serologic test (anti-HBc or anti-HBs);
P1 = prevalence of past infection/immunization;
P2 = percentage of recipients of first dose who actu-
ally receive a second dose;
P3 = percentage of recipients of doses 1 and 2 who
receive dose 3;
[P2 + P2(P3)] = average number of doses for a person
starting the series; and
v = cost per dose of vaccine, including administrative
costs.
* Using this formula for hepatitis A vaccination assumes no vaccination
is administered at the time of the blood draw. For hepatitis A
vaccination, T = cost of serologic test for anti-hepatitis A virus (HAV);
T = P1 x v. For more prevaccination information regarding hepatitis
A, see Appendix.
Testing for HBV Infection
Pregnant Women. HBsAg testing is recommended for all
pregnant women as soon as the pregnancy is recognized, irre-
spective of hepatitis B vaccination history or previous test
results (9,145–147). In addition, women with risk factors for
HBV infection during their pregnancy (e.g., intercurrent STDs,
multiple sex partners, sex partners and household contacts of
HBsAg-positive persons, or clinically apparent hepatitis) need
retesting for HBsAg late in pregnancy because of the high risk
for HBV infection (9,147). Women diagnosed with chronic
infection need evaluation for chronic liver disease, and close
contacts (e.g., sex, household, prison cell, or dormitory)
require vaccination because of their high risk for infection (9).
Prevaccination Testing. Proof of previous hepatitis B vac-
cination through an immunization registry, medical records,
or vaccination card can be used to determine whether to
exclude inmates from vaccination. When inmate vaccination
status is unknown, testing for immunity to HBV infection
can reduce vaccine cost among populations with high rates
for infection or vaccination coverage (Box 5). However, vacci-
nation of a person immune to HBV infection because of prior
vaccination or infection does not increase risk for adverse
events. Testing is not indicated before vaccination of adoles-
cents or younger children because of the low prevalence of
HBV infection in these age groups (9,148).
As hepatitis B vaccination coverage increases among adoles-
cents, a higher proportion of adults will be immune to HBV
infection. Correctional systems should be aware of state hepa-
titis B vaccination requirements for middle school entry, which
typically achieve high vaccination coverage. If adequate
immunization records are not routinely available for incom-
ing inmates, periodic serologic surveys are necessary to deter-
mine the prevalence of immunity to HBV infection and to
guide policies for prevaccination testing.
Among populations with a high prevalence of immunity as
a result of vaccination, testing for chronic HBV infection is
not warranted. However, among populations with a high preva-
lence of HBV infection, testing is necessary to identify
inmates with chronic HBV infection and initiate medical fol-
low-up and immunization of close contacts.
Postvaccination Testing. Testing to determine antibody
response to vaccination is not necessary for healthy juveniles
and adults (Appendix A). For immunocompromised persons
(e.g., hemodialysis patients or HIV-infected) and persons with
continued known exposure to HBV infection (e.g., infants
born to HBsAg-positive mothers, sex partners of HBsAg-
positive persons, or health-care workers), testing is needed to
verify response to vaccination and the need for possible revac-
cination, or to identify HBV infection (9,149,150)
Prevention of HBV Infection After Exposure
Immunization (active, passive, passive-active) within a rela-
tively short period of time after exposure to HBV can effec-
tively prevent acute and chronic infection. Initiation of the
hepatitis B vaccine series within 12–24 hours of exposure has
been demonstrated 70%–90% effective in preventing HBV
infection (131,151). The combination of vaccine and HBIG
achieves a similar level of efficacy (Box 6) (128,129). Among
known nonresponders to vaccination, 1 dose of HBIG is 70%–
90% effective in preventing hepatitis B when administered
within 7 days of a percutaneous HBV exposure. HBIG
administered within 2 weeks is also required for protection from
sexual exposure to a person with acute hepatitis B (152–154).
Detection of HBV Infection
Acute HBV Infection. Acute HBV infection is asymptom-
atic among 60%–70% of patients, but can have symptoms
and signs associated with acute viral hepatitis (e.g., loss of
appetite, nausea, vomiting, fever, abdominal pain, or
jaundice), and must be confirmed by serologic testing (Table 2,
Box 2). Treatment for acute hepatitis B is supportive, consist-
ing of rest, hydration, and symptomatic relief as needed. Iden-
tification of an inmate with acute HBV infection, especially
one who has been incarcerated >6 months, requires an epide-
miologic investigation by correctional officials, in collabora-
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TABLE 2. Interpretation of hepatitis B virus serologic testing
Serologic markers
Interpretation HBsAg* Total anti-HBc† IgM§ anti-HBc Anti-HBs¶
Susceptible, never infected – – – –
Acute infection, early incubation period** + – – –
Acute infection + + + –
Acute resolving infection – + + –
Past infection, recovered and immune – + – +
Chronic infection + + – –
False positive (i.e., susceptible), past infection, or low-level chronic infection – + – –
Immune from vaccination if antibody concentration >10 milli international units
per milliliter (mIU/mL) – – – +
* Hepatitis B surface antigen.
† Antibody to hepatitis B core antigen.
§ Immunoglobulin M.
¶ Antibody to hepatitis B surface antigen.
** Transient HBsAg positivity (lasting <21 days) might be detected in certain patients during vaccination.
BOX 6. Prophylaxis after exposure to hepatitis B virus (HBV)
Type of exposure
Perinatal
Sexual — acute case
Sexual — chronic HBV infection
Household (e.g., cell or dormitory) contact — to person with
chronic HGV infection
Household (e.g., cell or dormitory) contact — acute case





Vaccination. If not previously vaccinated, also admin-
ister HBIG if known exposure§
Vaccination. If not previously vaccinated, also admin-
ister HBIG if known exposure§
Vaccination +/- HBIG¶
Source: CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination—
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(No. RR-13):1–25.
* See Table 4.
† HBIG = hepatitis B immune globulin. Dosages: perinatal = 0.5 mL intramuscular; all other = 0.06 mL/kg, intramuscular.
§ Identifiable blood exposure to infected contact (e.g., by sharing toothbrushes or razors).
¶ See Table 5.
tion with the appropriate health authorities, to identify the
source of infection. Depending upon the results, vaccination
of sexual, prison cell, dormitory, and household (e.g., conju-
gal and other family members) contacts can be indicated.
Chronic HBV Infection. Chronic HBV infection can
be distinguished from acute infection by serologic testing
(Table 2). Inmates identified with chronic HBV infection
require evaluation to determine the extent of liver disease,
virus replication, indications for antiviral therapy (64), and
need for vaccination of contacts to prevent HBV transmission.
Management of Chronic HBV Infection
Initial evaluation of patients with chronic HBV infection
includes biochemical tests for liver disease (e.g., alanine ami-
notransferase [ALT], and aspartate aminotransferase [AST]),
for the extent of liver disease (e.g., serum albumin or pro-
thrombin time), and status of HBV replication (e.g., HBeAg,
antibody to HBeAg [anti-HBe], and HBV DNA). Alpha
interferon, lamivudine, or adefovir dipivoxil are approved by
the Food and Drug Administration (FDA) for treatment of
chronic hepatitis B (64,155). Therapy can be appropriate for
patients who have abnormal levels of liver enzymes, active
virus replication (HBeAg-positive or high levels of HBV
DNA), and a liver biopsy indicating presence of moderate dis-
ease activity and fibrosis (64).
Treatment with interferon, administered by injection 3 times/
week, substantially decreases HBV DNA levels and clears
HBeAg among >50% of patients with ALT levels >5 times the
upper limit of normal, and among 20%–35% of patients with
ALT levels 2–5 times the upper limit of normal. Among
patients with ALT levels <2 times the upper limit of normal,
response is poor and therapy should be deferred. Long-term
follow-up of treated patients indicates remission of chronic
hepatitis induced by alpha interferon is of long duration (64).
Patient characteristics associated with positive response to
interferon therapy include low pretherapy HBV DNA levels,
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high pretherapy ALT levels, short duration of infection,
acquisition of disease in adulthood, and histology indicative
of active inflammation.
Lamivudine, administered orally daily, has been as effective
as interferon at clearing HBeAg. Although a majority of
patients taking lamivudine demonstrate improved liver his-
tology, development of lamivudine-resistant HBV mutants is
common, especially with prolonged use, and diminishes the
effectiveness of treatment. Studies of lamivudine in combina-
tion with interferon have not been demonstrated to be supe-
rior to monotherapy (64).
The newest therapy to be approved is adefovir, which also is
administered orally daily. Patients treated with adefovir
exhibited substantial improvements in liver histology and
decreased levels of HBV DNA; however, durability of the
response has not been determined (156). Adefovir has been
demonstrated to be effective in patients with chronic hepatitis
B who have experienced resistance to lamivudine (156).
Treatment of persons coinfected with HIV and HBV
requires additional monitoring. After initiation of highly
active antiretroviral therapy (HAART) for treatment of HIV
infection, reactivation of HBV replication with development
of acute hepatitis has been observed among persons thought
to have resolved HBV infection. Although interferon treat-
ment is not as effective for patients coinfected with HIV, HBV
and HIV can be simultaneously treated (157).
Inmates identified with chronic HBV infection can benefit
from counseling regarding ways to prevent transmitting HBV
infection to others. Vaccination of sexual and nonsexual con-
tacts (e.g., cellmates) can also prevent transmission (9).
Current Practices: Prevention of HBV
in Correctional Settings
Juveniles. Juveniles in the justice system have been deter-
mined to have increased risk for HBV infection (125). In 2001,
a national survey of state juvenile correctional systems reported
that 36 (86%) of 42 responding systems had a hepatitis B
prevention program in place; 78% used the VFC program to
pay for vaccine; and 85% considered vaccination to be a cor-
rections responsibility while a juvenile is in custody. Written
hepatitis B prevention policies were in place in 65% of states,
and 27% used a vaccine tracking system or immunization reg-
istry (CDC, unpublished data, 2002).
In states with immunization registries and VFC participa-
tion, vaccination coverage among incarcerated juveniles has
reached levels >90% (G. Treder, Wisconsin Department of
Corrections, personal communication, 2002). However, where
the correctional system does not have legal guardianship of
the detained juvenile, the need for parental consent can pose a
barrier to vaccination. In states with laws enabling minors to
consent to their own STD-related treatment and prevention,
hepatitis B has been included, facilitating implementation of
vaccination programs (M. Staples-Horne, M.D., Georgia
Department of Juvenile Justice, personal communication,
2002).
Adults. Hepatitis B vaccination is recommended for adults
in correctional settings because of their increased risk for
infection, both inside and outside of prisons and jails
(9,33,34,100). Vaccinating inmates in prisons has been dem-
onstrated feasible and cost-saving from both prison and out-
side community perspectives (158) (CDC, unpublished data,
2002). Approximately 25 state correctional systems and the
Federal Bureau of Prisons have implemented hepatitis B
immunization programs, which vary in scope and are often
limited by funding or staffing resources. System policies
include immunization of 1) all incoming inmates; 2) inmates
of certain ages; 3) inmates with certain lengths of sentences;
4) inmates with HCV infection; or 5) inmates who request
vaccination. In certain correctional systems, inmates must pay
for vaccination (137,159). Among inmates in three systems
(in Massachusetts, Michigan, and Texas) that offer hepatitis B
vaccine, 60%–80% accept vaccination (T. Lincoln, M.D.,
Hampden County Correctional Center, Ludlow, Massachu-
setts; D. Thelen, Michigan State Department of Corrections;
M. Hurie, Michigan State Department of Health; and
M. Kelley, M.D., Texas Department of Criminal Justice; per-
sonal communications, 2001). Successful hepatitis B vaccina-
tion programs, like other successful adult vaccination programs
(e.g., influenza) include establishment of policies for vaccina-
tion and a source of payment for vaccine (160–163). Among
states, Hawaii, Michigan, Texas, and Wisconsin have exten-
sive experience in offering vaccine to inmates.
The Texas Department of Criminal Justice has 105 adult
facilities with approximately 145,000 inmates. In 1999, funds
were appropriated for hepatitis B vaccination of all offenders.
A cost analysis indicated prevaccination testing would be cost-
effective if prior HBV infection rates were >25%. However, a
seroprevalence study identified an HBV prevalence of 17.8%
and a history of vaccination among another 5.5%. Medical
records are reviewed for a history of hepatitis B vaccination or
evidence of HBV infection from prior clinical testing.
All inmates are offered vaccine, and the central pharmacy
delivers second and third doses of vaccine to the appropriate
housing units on a 0-, 2-, and 4-month vaccination schedule.
Scheduled vaccine doses are listed in each inmate’s medical
record to serve as an additional reminder to complete the vac-
cination series.
In the first 18 months of the program, 115,627 previously
incarcerated inmates initiated the vaccine series, and since
November 2001, the program has vaccinated all inmates at
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† Available at http://www.cdc.gov/ncidod/diseases/hepatitis/c/plan/strategy.pdf.
BOX 7. Persons for whom routine hepatitis C virus (HCV)
testing is recommended*
On the Basis of Risk for Infection, Persons
Who
• ever injected illegal drugs;
• received clotting factor concentrate produced before
1987;
• ever were on long-term hemodialysis;
• have evidence of chronic liver disease including per-
sistently abnormal levels of alanine aminotransferase
(ALT); or
• received a transfusion of blood or blood components
or an organ transplant before July 1992.
On the Basis of a Recognized Exposure,
• health-care, emergency medical, public safety, and cor-
rectional workers after needle sticks, sharps, or
mucosal exposure to HCV-positive blood; or
• children born to HCV-positive women.
Source: CDC. Recommendations for prevention and control of hepatitis
C virus (HCV) infection and HCV-related chronic disease. MMWR
1998;47(No. RR-19):1–39.
* Screening testing for antibody to HCV (anti-HCV) followed by
appropriate confirmatory testing for persons found to be screening test
positive.
entry — an estimated 35,000/year. The estimated cost for vac-
cination of 121,000 inmates during the first 18 months of the
program was $8 million, with an expected recurring annual
cost of $2.6 million to vaccinate incoming inmates (M. Kelley,
M.D., Texas Department of Criminal Justice, personal com-
munication, 2001).
Prevention of HCV Infection
Strategy To Prevent HCV Infection
CDC’s national strategy to prevent HCV infection includes
1) prevention of transmission during high-risk activities (e.g.,
injection-drug use and unprotected sex with multiple part-
ners) through risk-reduction counseling, testing, and appro-
priate medical management of infected persons; 2) donor
screening and product inactivation procedures to eliminate
transmission from blood, blood products, donor organs, and
tissue; and 3) improved infection control practices to further
reduce risk of transmission during medical procedures † (10).
Primary prevention is directed at lowering the incidence of
HCV infection. Of the estimated 25,000–40,000 persons
newly infected with HCV annually during the past 5 years,
approximately 60% acquired their infection through injec-
tion-drug use (45,111). Because no vaccine exists to prevent
HCV infection, prevention must focus on risk reduction
through counseling of persons who have admitted to or are at
risk for illicit drug use or high-risk sexual practices. Counsel-
ing and testing to prevent HCV infection should be conducted
in settings where persons at high risk are identified, including
correctional health programs, and clinics that treat STDs, HIV/
AIDS, and substance abuse (10) (Box 7).
The high prevalence of HCV infection and risk associated
with HCV infection among inmates requires inclusion of HCV
prevention activities in correctional settings. To be effective,
risk reduction among this population often requires a
multidisciplinary approach to address drug use as well as other
medical, psychological, social, vocational, and legal problems
(164).
Identification of HCV-infected persons is required to ini-
tiate secondary and tertiary prevention activities to reduce the
risks for HCV transmission and chronic liver disease (10).
Anti-HCV–positive persons require further evaluation for
chronic HCV infection and liver disease, and persons with
chronic hepatitis C require evaluation for possible antiviral
therapy and the need for further medical management.
Persons with chronic hepatitis C are at risk for increased
morbidity from additional hepatic insults. Fulminant hepati-
tis caused by hepatitis A can be prevented by vaccination (50).
HCV-infected persons often have risk factors for HBV infec-
tion; therefore, hepatitis B vaccination is also recommended
(10). Persons with hepatitis C should be counseled to not use
alcohol, because its use (>10g/day for women and >20g/day
for men) has been associated with more rapid progression to
cirrhosis, which puts patients at higher risk for HCC
(10,165,166).
Persons at risk for HCV infection or those chronically
infected with HCV can benefit from health education on topics
including 1) substance-abuse treatment where appropriate,
2) clean needle and syringe use, 3) risks of sharing drug para-
phernalia, and 4) condom use (10). Counseling and educa-
tional materials should include information concerning
reducing further liver damage, as well as treatment options for
those with chronic liver disease. Release planning should
include substance-abuse–treatment referrals for IDUs and
medical referrals to specialists for future medical management
and treatment (see juvenile and adult sections on health edu-
cation and release planning).
Testing for HCV Infection
Anti-HCV testing is recommended to identify infected per-
sons. To prevent reporting of false-positive results, testing
should include both an antibody screening assay (e.g., enzyme
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immunoassay [EIA]) and supplemental or confirmatory test-
ing with an additional, more specific assay (e.g., recombinant
immunoblot assay [RIBA,® Chiron Corporation, Emeryville,
California] for anti-HCV or nucleic acid testing for HCV
RNA). These tests detect anti-HCV in >97% of infected
patients but do not distinguish between acute, chronic, or
resolved infection (11). Substantial variation exists among labo-
ratories regarding the extent to which more specific testing is
performed. The level of the screening test signal-to-cut–off
ratio has been demonstrated to predict a true antibody-
positive result. Use of the signal-to-cut–off ratio limits supple-
mental testing to those samples for which the ratio is low (167).
Detection of HCV Infection
Acute Hepatitis C. Acute HCV infection is usually asymp-
tomatic (80%). However, acute hepatitis C should be included
in the differential diagnosis of inmates who have signs and
symptoms of acute hepatitis (Box 2). Confirmation of acute
hepatitis C requires negative test results for IgM anti-HAV
and IgM anti-HBc and a positive screening test result for
anti-HCV, verified by supplemental testing or a high signal-
to-cut–off ratio. Among a limited number of patients, onset
of symptoms may precede anti-HCV seroconversion, and fol-
low-up antibody testing might be necessary to make the diagnosis.
Identification of an inmate with acute hepatitis C, espe-
cially a person incarcerated for >6 months, requires initiation
of an epidemiologic investigation by correctional officials, in
collaboration with the appropriate health authorities, to iden-
tify the source of infection. Depending upon the results, test-
ing of contacts might be indicated.
Chronic HCV Infection. Anti-HCV alone does not dis-
tinguish between acute, chronic, or resolved infection. In per-
sons testing positive for anti-HCV, chronic HCV infection
can be distinguished by persistence of HCV RNA for >6
months.
Management of HCV Infection
HCV-positive persons benefit from evaluation for the pres-
ence and severity of chronic liver disease. Antiviral therapy is
recommended for persons with persistently elevated ALT lev-
els, detectable HCV RNA, and a liver biopsy that indicates
either portal or bridging fibrosis or moderate degrees of
inflammation and necrosis. No clear consensus exists on
whether to treat patients with persistently normal serum tran-
saminases. Information is available on the National Institute
of Health (NIH) website§ regarding regimens with proven
efficacy approved by the FDA for the treatment of chronic
hepatitis C (168). The FDA has approved three antiviral thera-
pies for treatment of chronic hepatitis C in persons aged >18
years: alpha interferon, pegylated interferon, and alpha or
pegylated interferon in combination with ribavirin. All are
administered for <52 weeks. Among persons with HCV geno-
type 1, the most common genotype in the United States, the
response rate to either of the interferons administered alone is
<20%, but the response rate to the combination of alpha
interferon and ribavirin is 30%–40%, and to pegylated inter-
feron and ribavirin, 40%–50%. Both the alpha and pegylated
interferons are administered by injection; ribavirin is taken
orally. All of these drug regimens have side effects, certain of
which can be serious. Successful treatment eliminates viremia
and the potentials for HCV transmission and further chronic
liver disease (168,169).
Among persons with both HCV and HIV infection, ben-
efits of therapy for chronic hepatitis C have only recently been
evaluated. The decision to treat persons coinfected with HIV
must take into consideration concurrent medications and
medical conditions (e.g., hyperthyroidism, renal transplant,
or autoimmune disease). If CD4 counts are normal or mini-
mally abnormal (>500/mL), treatment responses to interferon
monotherapy are similar to non-HIV–infected persons
(106,170,171). The efficacy of ribavirin/interferon combina-
tion therapy among HIV-infected persons has been tested in
only a limited number of patients. Ribavirin can have sub-
stantial interactions with other antiretroviral drugs (168). Each
patient should be evaluated by a physician familiar with the
treatment of patients with HCV infection and HIV infec-
tions when appropriate, and indications for therapy should be
reassessed at regular intervals.
Current Practices: Prevention of HCV
in Correctional Settings
Testing populations with high proportions of IDUs is an
efficient strategy for identifying HCV-positive persons (10).
However, in the correctional setting, only a limited number
of studies have examined willingness to be tested, treatment
options, compliance, and outcomes among those offered
therapy (122,172). In assessments of other prison screening
programs (e.g., for HIV and STDs), a relatively high rate
(approximately 50%) of refusal has been reported (173–175).
Limited data from studies in Rhode Island and Pennsylva-
nia indicate approximately 7%–27% of all inmates identified
with HCV infection ultimately begin treatment (122,172;
F. Maue, M.D., Pennsylvania State Department of Correc-
tions, personal communication, 2001). The majority of
inmates were excluded from treatment because of clinical
contraindications, short lengths of prison stay, and drug or
alcohol use (122,172; F. Maue, M.D., Pennsylvania State
Department of Corrections, personal communication, 2001).
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BOX 8. Elements of viral hepatitis health education
Health Education Programs and Curricula
Should Include
• routes of transmission;
• risk factors for infection;
• disease outcomes, the need for medical management
and treatment options;
• methods to prevent infection, including immuniza-
tion and harm and risk reduction;
• the importance of substance abuse treatment, when
appropriate;
• sexual precautions including abstinence counseling and
condom use;
• risk-reduction counseling, including not sharing drug
paraphernalia; and
• resources in the community available to support and
sustain a reduction in risk behaviors.
Less-restrictive criteria might increase the number of inmates
eligible for treatment (168). However, factors contributing to
acceptance and completion of treatment regimens need to be
identified to improve outcomes.
Health Education
Health education directed toward prevention of viral hepa-
titis includes information related to the disease, routes of trans-
mission, risk factors for infection, methods of prevention,
disease outcomes, and treatment options. During incarcera-
tion, numerous educational opportunities exist (e.g., at entry,
or in HIV-education and other classes). Education can take
different forms, including videos, brochures, and formal class-
room presentations. However, repeated face-to-face sessions
have been determined the most effective means with the high-
est retention (Box 8) (176–178). Model programs use peer
health educators in workshops for incoming inmates, and com-
munity educators to discuss risk assessment, risk reduction,
and referrals for soon-to-be released inmates.¶
Health education programs aimed at reducing risk of infec-
tion with hepatitis viruses include  discussion of hepatitis A
prevention, hygiene practices, and the significance of vaccina-
tion for persons at risk for infection. Curricula addressing HBV
and HCV infections include information concerning the simi-
lar modes of transmission and means for prevention, and
information about hepatitis B vaccination and risk reduction.
Such information can also be incorporated into health-
education programs for the prevention of HIV/AIDS.
Release Planning
Release planning is a relatively new component of health-
care management for incarcerated persons. The majority of
medical release and discharge planning programs in prison
facilities have focused on HIV aftercare (179,180), but
management of other chronic infections can result in the same
beneficial outcomes.
Comprehensive release planning includes transitional hous-
ing, continued access to discharge medications and immuni-
zations, and coordination and case-management of long-term
specialized care for persons with chronic conditions. Persons
diagnosed with chronic HBV infection can benefit from coun-
seling related to preventing transmission to household, sexual,
and drug-use contacts. Susceptible contacts of persons diag-
nosed with chronic HBV infection benefit from hepatitis B
vaccination. Persons with chronic hepatitis B or chronic hepa-
titis C can benefit from 1) counseling regarding ways to
reduce further liver damage, 2) referrals to substance-abuse–
treatment and other IDU programs if indicated, and 3) medi-
cal referrals to specialists for future treatment.
Rationale for Prevention
 and Control of Viral Hepatitis
in Correctional Settings
The high prevalence of chronic HBV and HCV infections
and risk factors for their transmission make prevention and
control of these infections high priorities for correctional health
programs. In addition, because a substantial proportion of
releasees to the community continue to acquire or transmit
these infections at a high rate, correctional efforts should
become part of prevention and control efforts in the broader
community.
Highly effective and safe vaccines are available to prevent
HAV and HBV infections. Identification of risk factors and
infection status, combined with harm- and risk-reduction
counseling, and substance-abuse treatment, have the poten-
tial to prevent HCV infections in the same manner they have
reduced the risk of HIV/AIDS. In addition, identification of
persons with chronic HBV and HCV infection provides
opportunities for medical evaluation and treatment of chronic
liver disease, and measures to prevent further transmission.
The feasibility of including viral hepatitis prevention activi-
ties in existing prevention programs has been demonstrated.
However, the challenges to integration of a comprehensive viral
hepatitis prevention and control program in correctional health
settings are substantial. They include budgetary and staffing
constraints, priorities that compete with preventive health care,
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and lack of communication among correctional health, pub-
lic health, and private health-care systems.
The recommendations for prevention and control of viral
hepatitis that follow are adapted to the correctional setting.
The objective of these recommendations is to reduce trans-
mission of hepatitis virus infections both during and after
incarceration. Implementation of these recommendations can
1) reduce transmission of HAV infection in the community
by immunizing incarcerated persons at highest risk for infec-
tion; 2) eliminate transmission of HBV infection among the
inmate population through immunization; 3) reduce the
number of new HCV infections by testing, harm- and risk-
reduction counseling, and substance-abuse treatment and pre-
vention; 4) reduce the burden of viral hepatitis-related chronic
liver disease through appropriate medical management; and
5) prevent HBV and HCV infections among correctional
employees.
Rating the Recommendations
The following recommendations are rated, where applicable,
on the basis of the strength of evidence indicating changes in
outcomes attributable to the interventions. Where formal rec-
ommendations previously have been published, they are cited
as supporting evidence and can be referred to for the original
studies. Ratings have been assigned by using a modification
of criteria published by the Guide to Community Preventive
Services (181). No rating was assigned to a recommendation
considered standard practice (i.e., a medical or administrative
practice conducted routinely by qualified persons experienced
in their fields).
• Strongly recommended (on the basis of >2 consistent, well-
conceived, well-executed studies with control groups or
longitudinal measurements).
• Recommended (on the basis of >1 well-conceived, well-
executed, controlled, or time-series study; or >3 studies
with more limited execution).
• Indicated (on the basis of previous scientific observation
and theoretic rationale, but case-controlled or prospec-
tive studies do not exist).
• Not recommended (on the basis of published literature
recommending against a practice).
Recommendations for Juvenile
 Correctional Facilities — Hepatitis A
Virus Infection
• Hepatitis A vaccination should be administered to all
juveniles in those states where routine vaccination is rec-
ommended (Box 1) (11). Strongly recommended.
• In all other states, hepatitis A vaccination of all juveniles
should be considered because of the high prevalence of
risk factors for HAV infection among this population (11).
Indicated.
• Vaccination should be administered to those juveniles with
risk factors for HAV infection (Box 1) or for those at risk
for severe adverse outcomes of infection (e.g., persons with
chronic liver disease) (11,57). Strongly recommended.
• Vaccination should be initiated as soon as possible after
entry into incarceration or detention using the appropri-
ate dosage and schedule (standard practice) (Table 3).
• Tracking systems to ensure completion of vaccine series
within the correctional system should be established, and
systems should be established to facilitate completion of
the vaccine series in the community (standard practice).
• Vaccination information, including date of administra-
tion, dose, and manufacturer should be included in the
medical record, and an immunization record should be
given to juvenile, or their parents or guardians, upon
release (standard practice).
• Routine screening or prevaccination testing of juveniles
for markers of HAV infection should not be conducted
(11). Not recommended.
• Prevaccination testing should be considered for older ado-
lescents (e.g., >15 years) in certain population groups (i.e.,
American Indians, Alaska Natives, and Hispanics) because
of higher prevalence of infection or previous infection (11).
Indicated.
• Juveniles with signs or symptoms indicative of acute hepa-
titis should have appropriate diagnostic testing to differ-
entiate acute hepatitis A, hepatitis B, or hepatitis C and to
TABLE 3. Hepatitis A vaccination dosages and schedule
Vaccine and Volume No. of Schedule
recipient ages (yrs) Dose (mL) doses (mos)
Havrix®*
2–18 720 EL.U.† 0.5 2 0 and 6–12
>18 1,440 EL.U.† 1.0 2 0 and 6–12
VAQTA®§
2–18 25 U 0.5 2 0 and 6–18
>18 50 U 1.0 2 0 and 6
Twinrix®¶**
>17 720 EL.U.† 1.0 3 0, 1, and 6
Sources: CDC. Notice to readers: FDA approval for a combined hepatitis A
and B vaccine. MMWR 2001;50:806–7. CDC. Prevention of hepatitis A
through active or passive immunization—recommendations of the Advi-
sory Committee on Immunization Practices (ACIP). MMWR 1999;48
(No. RR–12):1–37.
* Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium.
† Enzyme-linked immunosorbent assay (ELISA) units.
§ Manufactured by Merck & Co. Inc., Whitehouse Station, New Jersey.
¶ Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium.
** Twinrix also contains hepatitis B vaccine antigen.
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TABLE 4. Recommended dosages of licensed hepatitis B vaccines
Recombivax HB®*† Engerix-B®*§ Twinrix®¶
Age group (yrs) µg mL µg mL µg mL
Persons <19 (including infants born to HBsAg mothers) 5 0.5 10 0.5 — —
Persons 11–15 10 1.0** — — — —
Persons >20 10 1.0 20 1.0 20†† 1.0
Dialysis patients and other immunocompromised persons 40 1.0§§ 40 2.0¶¶ — —
* Both vaccines are routinely administered in a 3-dose series, which includes schedules of 0, 1, and 6 months; 0, 2, and 4 months; 0, 2, and 6 months; and,
for adolescents, 0, 12, and 24 months.
† Manufactured by Merck & Co. Inc., Whitehouse Station, New Jersey.
§ Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium.
¶ Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium.
** Administered in a 2-dose schedule at 0 and 4–6 months.
†† Twinrix is only licensed for persons aged >17 years, and contains both hepatitis A and hepatitis B vaccine antigens administered as a 3-dose schedule.
§§ Special formulation.
¶¶ Two 1.0-mL doses administered at one site, in a 4-dose schedule at 0, 1, 2, and 6 months.
determine if the patients have chronic HBV or HCV
infection (Box 2) (standard practice).
— Cases of acute hepatitis A should be reported to the
appropriate public health jurisdiction (e.g., county or
state health department) (standard practice).
— Identification of a case of hepatitis A in a correctional
facility should prompt an epidemiologic investigation
by correctional officials, in collaboration with the ap-
propriate health authorities, to identify the source of
infection and contacts who might have been exposed
(standard practice).
— Unvaccinated close contacts of a confirmed case of
hepatitis A should be administered postexposure pro-
phylaxis with 1 dose of IG (0.02 mL/kg body weight,
intramuscular) as soon as possible, but not >2 weeks
after the last exposure. If the contact has indications
for hepatitis A vaccination, vaccine should be admin-
istered either at the same or a later time (Box 3) (11).
Strongly recommended.
Recommendations for Juvenile
Correctional Facilities — Hepatitis B
Virus Infection
Preventing Perinatal HBV Infection
• All pregnant incarcerated juveniles should be tested for
HBsAg after their pregnancy is recognized, even if previ-
ously vaccinated or tested. Because of the high risk of HBV
infection among this population, testing should be per-
formed even if the female was tested before incarceration.
The HBsAg status of incarcerated pregnant juveniles
should be reported to the hospital where the juvenile will
deliver her infant, along with other prenatal medical
information. HBsAg-positive females should also be
reported to the appropriate public health authority (9).
Strongly recommended.
• Infants born to HBsAg-positive mothers should receive
HBIG (0.5 mL) and the first dose of hepatitis B vaccine
<12 hours of birth (Table 4) (9). Strongly recommended.
• Females admitted for delivery without HBsAg test results
should have blood drawn for testing. While test results
are pending, the infant should receive hepatitis B vaccine
without HBIG within 12 hours of birth (Table 4) (stan-
dard practice).
— If the mother is later determined to be HBsAg-posi-
tive, her infant should receive HBIG as soon as pos-
sible, but <7 days after birth. If the infant does not
receive HBIG, the second dose of vaccine should be
administered at 1 month of age. The final dose should
be administered at age 6 months (Table 4) (9). Strongly
recommended.
— If the mother is determined to be HBsAg-negative, her
infant should continue to receive hepatitis B vaccine
as part of the routine vaccination schedule (Table 4)
(9). Strongly recommended.
— If the mother is never tested to determine her HBsAg
status, the infant should continue to receive hepatitis
B vaccine as part of the routine vaccination schedule
(Table 4) (9). Strongly recommended.
• Case management should be established to ensure appro-
priate postexposure prophylaxis and follow-up for chil-
dren born to incarcerated or recently released
HBsAg-positive mothers, including completion of the
vaccine series at age 6 months and postvaccination test-
ing during ages 9–15 months (9,182). Recommended.
• Infants born to HBsAg-negative mothers should receive
the first dose of hepatitis B vaccine before release from the
hospital (9,142,143). Strongly recommended.
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• Previously unvaccinated HBsAg-negative pregnant juve-
niles should be vaccinated; pregnancy is not a contraindi-
cation to vaccination (9,183–185). Strongly
recommended.
• Discharge planning for pregnant HBsAg-positive juveniles
should include transfer of appropriate medical records to
the hospital where the juvenile plans to deliver her infant,
along with other prenatal medical information. Test re-
sults should also be provided to the patient and her par-
ent or guardian (standard practice).
Hepatitis B Vaccination
Preexposure
• All juveniles who receive a medical evaluation in a correc-
tional facility should be administered hepatitis B vaccine,
unless they have proof of completion of the vaccine series
or serologic evidence of immunity to infection. The vac-
cine series should be started for those juveniles who have
never been vaccinated, irrespective of their length of stay,
and the series should be completed for those incompletely
immunized (9,142,143,186,187). Strongly recommended.
— For juveniles who do not receive medical evaluation
upon entry into correctional custody, vaccination
should be considered for those who lack proof of pre-
vious vaccination (125) (standard practice).
— Catch-up vaccination of previously unvaccinated,
already incarcerated juveniles should be considered in
facilities in which routine hepatitis B vaccination of
entering inmates is established (33) (standard practice).
• An appropriate vaccination dose and schedule should be
selected to facilitate completion of the vaccine series while
the juvenile is in custody. For previously unvaccinated
juveniles held in a correctional facility for <6 months, the
vaccine series should be initiated and completed by using
a 4-month schedule (0, 1–2, and 4 months) (Table 4)
(186–189). Recommended.
• Vaccination information, including date of administra-
tion, dose, and manufacturer should be included in the
medical record, and an immunization record should be
given to juveniles, or to their parents or guardians, upon
release (standard practice).
• Discharge planning should include transfer of immuni-
zation records to the person’s medical home to ensure
completion of the vaccine series for those juveniles not
fully vaccinated while in the correctional facility, and for
all fully vaccinated persons as well (standard practice).
Prevaccination and Postvaccination Testing
• Prevaccination serologic testing is not indicated (148).
Indicated.
— As hepatitis B vaccination coverage among adolescents
increases, validation of immunization records or sero-
logic testing might become a cost-effective means to
minimize overvaccination. Indicated.
— Knowledge of state middle school hepatitis B vaccina-
tion requirements and performance of periodic vac-
cine coverage serologic surveys to determine the
proportion of vaccinated or immune adolescents
entering juvenile facilities should be used to define
prevaccination screening policies (e.g., history or sero-
logic testing) and the need for hepatitis B immuniza-
tion among specific age groups (standard practice).
• Postvaccination testing should not be conducted for
healthy juveniles (9,142,143,190). Not recommended.
• For juveniles with special conditions (e.g.,
immunocompromised or HIV-infected), postvaccination
testing for anti-HBs should be conducted 1–2 months
after completion of the vaccine series. Nonresponders in
this category should be revaccinated (149,150). Strongly
recommended.
Postexposure Prophylaxis
• After any percutaneous exposure (e.g., sharing injection-
drug equipment or human bite) or mucosal exposure (e.g.,
sexual) to blood, unvaccinated juveniles should begin the
vaccine series, and the exposure incident should be evalu-
ated to determine if additional postexposure prophylaxis
(i.e., HBIG) is required (Table 5) (9,47). Strongly recom-
mended.
— The first dose of hepatitis B vaccine should be admin-
istered immediately, and the remaining doses, 1 and 6
months later (standard practice).
— For an exposed juvenile who has begun but not com-
pleted the vaccine series, subsequent vaccine doses
should be administered as scheduled (standard practice).
— The person who was the source of the exposure should
be tested for HBsAg, even if this person was previ-
ously vaccinated. If the source person is HBsAg-
positive, HBIG should be administered to the exposed
person as soon as possible and <7 days after the expo-
sure (standard practice).
— Postexposure prophylaxis is not necessary for a fully
vaccinated juvenile after exposure to HBV (9,47). Not
recommended.
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TABLE 5. Postexposure prophylaxis for exposure to hepatitis B virus
Vaccination and antibody response Treatment when source is found to be






Source: CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommenda-
tions for postexposure prophylaxis. MMWR 2001;50 (No. RR-11):1–52.
* Persons who have previously been infected with HBV are immune to reinfection and do not require postexposure prophylaxis.
† Hepatitis B immune globulin; dose is 0.06 mL/kg body weight intramuscularly.
§ Hepatitis B vaccine.
¶ A responder is a person with adequate levels of serum antibody to HBsAg (i.e., anti-HBs >10 mlU/mL).
** A nonresponder is a person with inadequate response to vaccination (i.e., anti-HBs <10 mlU/mL).
†† The option of administering one dose of HBIG and reinitiating the vaccine series is preferred for nonresponders who have not completed a second 3-dose
vaccine series. For persons who previously completed a second vaccine series but failed to respond, 2 doses of HBIG are preferred.
§§ Hepatitis B surface antigen.
¶¶ Antibody to HBsAg.
Positive
HBIG† x 1, and initiate HB vaccine series§
No treatment
HBIG x 2, or HBIG x 1 and initiate
re-vaccination††
Test exposed person for anti-HBs¶¶
1. If adequate, no treatment is necessary.¶
2. If inadequate, administer HBIG x 1 and








Unknown or not available for testing
Initiate HB vaccine series
No treatment
If known high-risk source, treat as if
source were HBsAg§§ positive.
Test exposed person for anti-HBs¶¶
1. If adequate, no treatment is
necessary.¶
2. If inadequate, administer HBIG x 1
and vaccine booster, recheck anti-
HBs level in 1 month.
Serologic Testing for Hepatitis B Virus
Infection
• Routine testing of juveniles for markers of HBV infection
(e.g., HBsAg, anti-HBs, anti-HBc) is not recommended
(5,76,81,148,191). Not recommended.
• Juveniles with signs or symptoms indicative of viral hepa-
titis should have appropriate diagnostic testing to differ-
entiate acute hepatitis A, hepatitis B, or hepatitis C and to
determine if the patient has chronic HBV or HCV infec-
tion (Box 2) (standard practice).
— Cases of acute hepatitis B should be reported to the
appropriate public health authority (standard practice).
— Cases of chronic HBV infection should be reported in
those states that require reporting (standard practice).
• Identification of a case of acute hepatitis B should prompt
an epidemiologic investigation by correctional officials,
in collaboration with the appropriate health authorities,
to identify the source of infection and provide appropri-
ate postexposure prophylaxis (Table 5) (Box 6) to
nonimmunized contacts at risk for infection (standard
practice).
Chronic Hepatitis B Treatment
• Juveniles identified as having, or who are known to have
chronic HBV infection during routine medical screening
should be evaluated to determine the presence and extent
of chronic liver disease and candidacy for antiviral therapy
(64,192,193). Recommended.
— Lamivudine can be used to treat patients aged >2 years.
— The safety and efficacy of interferon and adefovir in
pediatric patients has not been established.
— Treatment of patients with chronic hepatitis B should
be conducted in consultation with a pediatric special-
ist experienced with these treatment regimens.
• All long-term correctional facilities should establish crite-
ria for identification of inmates who might benefit from
treatment, on the basis of the latest treatment guidelines
(standard practice).
• Discharge planning for persons with chronic HBV infec-
tion should include referral to medical care, risk-
reduction programs, and social services necessary to main-
tain behavior changes; vaccination of contacts should also
be arranged before patient discharge (standard practice).
Recommendations for Juvenile
Correctional Facilities — Hepatitis C
Virus Infection
Testing for Hepatitis C Virus Infection
• A history of risk factors for HCV infection should be
obtained from juveniles undergoing medical evaluations,
and those with risk factors should be tested for anti-HCV
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(Box 7). Routine testing of all juveniles for anti-HCV
should not be conducted (10). Not recommended.
• Juveniles with signs or symptoms indicative of viral hepa-
titis should have appropriate diagnostic testing to differ-
entiate acute hepatitis A, hepatitis B, or hepatitis C and to
determine if the patient has chronic HBV or HCV infec-
tion (Box 2) (standard practice).
• Cases of acute hepatitis C should be reported to the
appropriate public health authority (standard practice).
• Anti-HCV–positive persons should be reported if required
by state laws or regulations (standard practice).
• Identification of juveniles with acute hepatitis C, includ-
ing those incarcerated for >6 months, should prompt an
epidemiologic investigation by correctional officials, in
collaboration with the appropriate health authorities, to
identify the source of the infection. Depending on the
results of the investigation, testing of contacts might be
indicated (Box 7) (standard practice).
• Juveniles who are anti-HCV–positive should receive fur-
ther medical evaluation to determine if they are chroni-
cally infected (Box 2) (standard practice).
Postexposure Management for HCV
• After a percutaneous or permucosal exposure to blood,
the source person should be tested for anti-HCV. If the
source person is anti-HCV–positive, the exposed person
should be tested for anti-HCV and ALT activity at baseline
and 4–6 months later. For earlier diagnosis, testing for
HCV RNA can be performed in 4–6 weeks (10). Recom-
mended.
• IG and antiviral agents are not recommended for
postexposure prophylaxis of hepatitis C (10). Not recom-
mended.
Chronic Hepatitis C Treatment
• Juveniles identified as having chronic HCV infection
should be evaluated to determine the presence and extent
of chronic liver disease. FDA-approved antiviral agents
for treatment of hepatitis C are not indicated for persons
aged <18 years, although participation in clinical trials
might be possible. Although HCV infection in juveniles
can result in less severe disease, infected juveniles should
be monitored by a specialist familiar with this disease.
Discharge planning should also include drug and alcohol
abuse treatment, risk-reduction programs, and social ser-
vices necessary to maintain behavior changes (standard
practice).
• Juveniles with chronic hepatitis C should receive hepati-
tis B vaccination and hepatitis A vaccination if not previ-




• Prevention of HAV, HBV, and HCV infections should be
incorporated into health education programs (e.g., pro-
grams for preventing HIV/AIDS) and include informa-
tion concerning modes of disease transmission and means
for prevention, including risk-reduction and immuniza-
tion (Box 8) (17,177). Indicated.
• An integrated health education and risk reduction pro-
gram should be established in each facility and include a
written plan of health instruction completed by each
inmate (standard practice).
• Such instruction should address a range of issues relevant
to the diverse developmental and cultural composition of
correctional populations, and should include basic skill
development, literacy, and home economics, as well as
tools needed to avoid behaviors that result in acquisition
of HIV, hepatitis, and other bloodborne and sexually trans-
mitted infections (standard practice).
• Teachers should be trained professionals or inmate peers
with specific training to teach comprehensive life-skills
programs, including health education (standard practice).
• A system for periodic evaluation, updating and improve-
ment should exist (standard practice).
• Documentation of hepatitis A or hepatitis B vaccination
should be included in the medical record retained within
the correctional system, as well as in any medical record
provided to other health-care providers. In addition, vac-
cinated persons or their parents or guardians should be
provided a personal immunization record (standard prac-
tice).
• Juvenile correctional health facilities should establish links
with community and public health facilities, and where
available, with immunization registries, to ensure track-
ing and completion of hepatitis A and hepatitis B vaccine
series (standard practice).
• Juveniles with chronic HBV or HCV infection should be
— counseled, along with their parent or guardian, regard-
ing preventing transmission to household, sexual, and
drug-use contacts;
— provided referral for hepatitis B vaccination of contacts;
— counseled regarding ways to reduce further liver dam-
age, including limiting alcohol and drug use, and
afforded substance-abuse treatment when appropriate;
and
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— provided aftercare that includes medical follow-up
(standard practices).
Recommendations for Adult
Correctional Facilities — Hepatitis A
Virus Infection
• Hepatitis A vaccination should be administered to adults
in groups at risk for HAV infection (e.g., MSM or drug
users) or who are likely to experience severe adverse out-
comes of infection (e.g., persons with chronic liver dis-
ease) (Box 1) (11). Strongly recommended.
• For persons at risk, the vaccination series should be initi-
ated as soon as possible after incarceration using the
appropriate dosage and schedule (Table 3). Tracking sys-
tems to ensure completion of the vaccine series within the
correctional system should be established, and systems
should be developed to facilitate completion of the sec-
ond vaccine dose for those inmates who return to the com-
munity (11). Strongly recommended.
• Prevaccination serologic testing to identify susceptible
persons should be considered if determined to be cost-
effective (Box 5), and it does not compromise initiation
of vaccination. Inmates aged >40 years and those from
regions of high endemicity (see Appendix) should be con-
sidered for prevaccination testing because of the high
prevalence of past HAV infection among these groups (11).
Indicated.
• Routine screening of adults for anti-HAV should not be
conducted, except when used to identify susceptible per-
sons for vaccination (11). Not recommended.
• Vaccination information, including date of administra-
tion, dose, and manufacturer should be included in the
medical record, and an immunization record should be
given to the inmate upon release (standard practice).
• Adults with signs or symptoms indicative of acute hepati-
tis should have appropriate diagnostic testing to differen-
tiate acute hepatitis A, hepatitis B, or hepatitis C, and to
determine if the patient has chronic HBV or HCV infec-
tion (Box 2) (standard practice).
— Cases of hepatitis A should be reported to the appro-
priate public health authority (standard practice).
— Identification of a case of hepatitis A in a correctional
facility should prompt an epidemiologic investigation
by correctional officials, in collaboration with the
appropriate health authorities, to identify the source
of infection and contacts that might have been exposed
(standard practice).
— Unvaccinated or known susceptible close contacts of a
confirmed case of hepatitis A should be administered
postexposure prophylaxis with a single dose of IG (0.02
mL/kg body weight, intramuscular) as soon as pos-
sible, but not >2 weeks after the last exposure (Box 3)
(11). Strongly recommended.
Recommendations for Adult
Correctional Facilities — Hepatitis B
Virus Infection
Preventing Perinatal HBV Infection
• All pregnant women should be tested for HBsAg after
their pregnancy is recognized, even if previously vacci-
nated or tested. Because of the high risk for HBV infec-
tion among this incarcerated population, testing should
be performed even if the woman was tested before incar-
ceration. The HBsAg status of a pregnant woman should
be reported to the hospital where she will deliver her
infant, along with other prenatal medical information.
HBsAg-positive women should also be reported to the
appropriate public health authority (9). Strongly recom-
mended.
• Infants born to HBsAg-positive mothers should receive
HBIG (0.5 mL) and the first dose of hepatitis B vaccine
<12 hours after birth (Table 4) (9). Strongly recommended.
• Females admitted for delivery without HBsAg test results
should have blood drawn for testing. While test results
are pending, the infant should receive hepatitis B vaccine
without HBIG within 12 hours of birth (Table 4) (stan-
dard practice).
— If the mother is later determined to be HBsAg-
positive, her infant should receive HBIG as soon as
possible, but <7 days after birth. If the infant does not
receive HBIG, the second dose of vaccine should be
administered at 1 month of age. The final dose should
be given at age 6 months (Table 4). Strongly recom-
mended.
— If the mother is determined to be HBsAg-negative, her
infant should continue to receive hepatitis B vaccine
as part of the routine vaccination schedule (Table 4).
Strongly recommended.
— If the mother is never tested to determine her HBsAg
status, the infant should continue to receive hepatitis
B vaccine as part of the routine vaccination schedule
(Table 4). Strongly recommended.
• Case management should be established to ensure appro-
priate postexposure prophylaxis and follow-up for chil-
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dren born to incarcerated or recently released HBsAg-posi-
tive mothers, including completion of the vaccine series
at age 6 months and postvaccination testing during ages
9–15 months (9,182). Recommended.
• Infants born to HBsAg-negative mothers should receive
the first dose of hepatitis B vaccine before release from the
hospital (9,130). Strongly recommended.
• Previously unvaccinated HBsAg-negative pregnant women
should be vaccinated; pregnancy is not a contraindica-
tion to vaccination (9,183–185). Strongly recommended.
• Discharge planning for pregnant HBsAg-positive women
should include transfer of appropriate medical records to
the hospital where the woman plans to deliver her infant,
along with other prenatal medical information. Test




• All adults who receive a medical evaluation in a correc-
tional facility should be administered hepatitis B vaccine,
unless they have proof of completion of the vaccine series
or serologic evidence of immunity to infection. The vac-
cine series should be started for those who have never been
vaccinated, irrespective of the length of their stay, and the
series should be completed for those incompletely immu-
nized (9,142,143,190). Strongly recommended.
— For persons who did not receive medical evaluation
upon entry into correctional custody, vaccination
should be considered for those who lack proof of pre-
vious vaccination or immunity (9,142,143). Recom-
mended.
— Catch-up vaccination of already incarcerated, previ-
ously unvaccinated persons, or persons known to be
susceptible to infection, should be considered in
facilities in which routine hepatitis B vaccination of
entering inmates is being established. Priority should
be given to vaccination of contacts of known HBsAg-
positive persons (e.g., cellmates or persons living in
the same cell block or dormitory) (33,101,102). Rec-
ommended.
• An appropriate vaccination dose and schedule should be
selected to facilitate completion of the vaccine series while
the person is in custody. For previously unvaccinated per-
sons held in a correctional facility for <6 months, the vac-
cine series should be initiated and completed by using a
4-month schedule (0, 1–2, and 4 months) (Table 4) (186–
189). Recommended.
• Vaccination information, including date of administra-
tion, dose, and manufacturer should be included in the
medical record, and an immunization record should be
given to the incarcerated person upon release (standard
practice).
• Discharge planning should include transfer of immuni-
zation records to the person’s medical home to ensure
completion of the vaccine series for persons not fully vac-
cinated while in the correctional facility, and for all fully
vaccinated persons as well (standard practice).
Prevaccination and Postvaccination Testing
• Prevaccination serologic testing should be considered for
adult incarcerated populations and is likely to be cost-
effective when the prevalence of immunity from prior
infection and vaccination exceeds 25%–30% (Box 5)
(148). Indicated.
— To assist correctional facilities in determining whether
to conduct prevaccination testing, periodic serologic
surveys of incoming inmates can be used to determine
the prevalence of markers of immunity to HBV infec-
tion (standard practice).
— Testing for anti-HBs provides the best measure of
immunity to HBV infection, because it detects infec-
tion or vaccine-induced immunity (standard practice).
— When prevaccination testing is done, the first dose of
vaccine should be administered at the same time the
blood sample is obtained to ensure optimal vaccina-
tion coverage (Box 5) (9). Recommended.
• Postvaccination testing is not indicated for healthy adults
(9,142,143). Not recommended.
• For persons with special conditions (e.g., immunodefi-
ciency, HIV infection, or chronic hemodialysis), or who
are likely to be exposed to HBV (e.g., sex partner of
HBsAg-positive person or health-care worker), postvacci-
nation testing for anti-HBs is recommended 1–2 months
after completion of the vaccination series. Nonresponders
in this category should be revaccinated (149,150). Strongly
recommended.
Postexposure Prophylaxis
• After any percutaneous (e.g., sharing injection-drug equip-
ment or human bite) or mucosal (e.g., sexual) exposure to
blood, an unvaccinated person should begin the vaccine
series, and the exposure incident should be evaluated to
determine if additional postexposure prophylaxis (i.e.,
HBIG) is required (Table 5) (9,47). Strongly recom-
mended.
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— The first dose of hepatitis B vaccine should be admin-
istered immediately, and the remaining doses 1 and 6
months later (Table 4) (standard practice).
— For an exposed person who has begun but not com-
pleted the vaccine series, subsequent vaccine doses
should be administered as scheduled (standard practice).
— The person who was the source of the exposure should
be tested for HBsAg, even if that person was previ-
ously vaccinated. If the source person is HBsAg-posi-
tive, HBIG (0.06 mL/kg body weight intramuscular)
should be administered to the exposed person as soon
as possible and <7 days after the exposure (standard
practice).
— Postexposure prophylaxis is not necessary for a fully
vaccinated person after exposure to HBV (9,47,138).
Not recommended.
Serologic Testing for Hepatitis B Virus
Infection
• Correctional facilities should consider routine testing of
long-term inmates for chronic HBV infection (Box 2,
Table 2), to facilitate rapid vaccination of contacts, direct
counseling for preventing secondary transmission, and
ensure medical evaluation of infected persons. If routine
testing is not performed, testing should be considered for
inmates in groups with risk factors for chronic HBV
infection (e.g., injection-drug use, MSM or foreign-born
persons from countries with high rate of infection). Indi-
cated.
• Residents of any facility with signs or symptoms indica-
tive of viral hepatitis should have appropriate diagnostic
testing to differentiate acute hepatitis A, hepatitis B, and
hepatitis C and to determine if the patient has chronic
HBV or HCV infection (Box 2) (standard practice).
— Cases of acute hepatitis B should be reported to the
appropriate public health authority (standard practice).
— If an inmate is identified as having chronic HBV in-
fection, the case should be reported in those states where
reporting is required (standard practice).
— Identification of acute hepatitis B should prompt an
epidemiologic investigation by correctional officials,
in collaboration with the appropriate health authori-
ties, to identify the source of infection and provide
appropriate postexposure prophylaxis (Box 6, Table 4)
to nonimmunized contacts at risk for infection (stan-
dard practice).
— Persons diagnosed with acute hepatitis B should be
observed for progressive liver dysfunction and evidence
of acute liver failure (standard practice).
Chronic Hepatitis B Treatment
• Inmates identified as having chronic HBV infection dur-
ing medical screening should be evaluated to determine
the presence and extent of chronic liver disease and the
potential benefit of antiviral therapy. Therapies for treat-
ment of hepatitis B include interferon, alpha, lamivudine,
and adefovir. Treatment of patients with chronic hepatitis
B should be conducted in consultation with a specialist
experienced with these treatment regimens (standard prac-
tice).
• All long-term correctional facilities should establish crite-
ria for identifying prisoners who might benefit from treat-
ment, on the basis of the latest treatment guidelines
(standard practice).
• Discharge planning for persons with chronic HBV infec-
tion should include referral to medical care, risk-
reduction programs, and social services necessary to main-
tain behavior changes; vaccination of contacts should also
be arranged before patient discharge (standard practice).
Recommendations for Adult
Correctional Facilities — Hepatitis C
Virus Infection
Testing for Hepatitis C Virus Infection
• All inmates should be asked questions regarding risk fac-
tors for HCV infection during their entry medical evalu-
ations, and all inmates reporting risk factors for HCV
infection should be tested for anti-HCV (Box 7) (10;
J. Pfister, M.S., Wisconsin State Laboratory of Hygiene;
T. Lincoln, M.D., Hampden County Correctional Cen-
ter, Ludlow, Massachusetts; personal communications;
2001). Recommended.
• The sensitivity of risk factor-based screening should be
periodically determined by seroprevalence surveys, in com-
bination with ascertainment of demographic and risk-
factor information. Serologic testing of expanded groups
of inmates or all inmates is recommended when
— self-reported history of risk factors alone identifies
<75% of anti-HCV positive inmates; or
— the prevalence of risk factors for HCV infection,
including injection-drug use, is known to be high
(>75%), and a high prevalence exists (>20%) of HCV
infection among inmates who deny risk factors (stan-
dard practices).
• Anti-HCV–positive persons should be reported if required
by state regulations (standard practice).
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• Adults with signs or symptoms indicative of viral hepati-
tis should have appropriate diagnostic testing to differen-
tiate acute hepatitis A, hepatitis B, or hepatitis C and to
determine if the patient has chronic HBV or HCV infec-
tion (Box 2) (standard practice).
— Cases of acute hepatitis C should be reported to the
appropriate public health authority (standard practice).
— Identification of an inmate with acute hepatitis C,
including ones who have been incarcerated for >6
months, should prompt an epidemiologic investiga-
tion by correctional officials, in collaboration with the
appropriate health authorities, to identify the source
of the infection. Depending on the results of the
investigation, testing of contacts might be indicated
(Box 7) (standard practice).
• Adults who test positive for anti-HCV should receive fur-
ther medical evaluation to determine chronic infection
and liver disease (standard practice).
Postexposure Management for HCV
• After a percutaneous or permucosal exposure to blood,
the source person should be tested for anti-HCV. If the
source person is anti-HCV–positive, the exposed person
should be tested for anti-HCV and ALT activity at baseline
and 4–6 months later. For earlier diagnosis, testing for
HCV RNA can be performed at 4–6 weeks (10). Recom-
mended.
• IG and antiviral agents are not recommended for
postexposure prophylaxis of hepatitis C (10). Not recom-
mended.
Chronic Hepatitis C Treatment
• All anti-HCV–positive inmates should be evaluated for
evidence of chronic HCV infection, including the pres-
ence and extent of chronic liver disease and candidacy for
antiviral therapy. Treatment of patients with chronic hepa-
titis C should be conducted in consultation with a spe-
cialist familiar with these treatment regimens (standard
practice).
• Inmates with chronic hepatitis C should receive hepatitis
B vaccination and hepatitis A vaccination if not previ-
ously immunized or known to be susceptible to infection
(9–11,50). Recommended.
• Correctional facilities or systems should establish criteria
based on the latest treatment guidelines for the identifica-
tion of prisoners who might benefit from antiviral treat-
ment. For HCV-infected patients who are actively abusing
substances (e.g., drugs or alcohol), appropriate substance-
abuse treatment should be initiated to limit disease trans-




• Prevention of HAV, HBV, and HCV infection should be
incorporated into health education programs (e.g., pro-
grams for preventing HIV/AIDS) and include informa-
tion concerning modes of disease transmission, methods
for prevention, including risk reduction and immuniza-
tion, disease outcomes, and options for treatment (Box 8)
(176,177). Indicated.
• An integrated health education and risk reduction pro-
gram should be established in each facility and include a
written plan of health instruction completed by each
inmate (standard practice).
• Such instruction should address a range of issues relevant
to the diverse developmental and cultural composition of
correctional populations, and should include basic skill
development, literacy, and home economics, as well as
tools needed to avoid behaviors that result in acquisition
of HIV, hepatitis, and other bloodborne and sexually trans-
mitted infections (standard practice).
• Teachers should be trained professionals or inmate peers
with specific training to teach comprehensive life-skills
programs, including health education (standard practice).
• A system for periodic evaluation, updating and improve-
ment should exist (standard practice).
• Documentation of hepatitis A or hepatitis B vaccination
should be included in the medical record retained within
the correctional system, as well as in any medical record
provided to other health-care providers. In addition, the
vaccinated person should be provided a personal immu-
nization record (standard practice).
• Correctional health facilities should establish links with
community and public health facilities, and where avail-
able, with immunization registries, to ensure tracking and
completion of hepatitis A and hepatitis B vaccine series
(standard practice).
• Persons with chronic HBV or HCV infection should be
— counseled regarding preventing transmission to house-
hold, sexual, and drug-use contacts, including risk
reduction and condom use;
— provided referral for hepatitis B vaccination of contacts;
— counseled regarding ways to reduce further liver dam-
age, including limiting alcohol and drug use, and
afforded substance-abuse treatment when appropriate;
and
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— provided aftercare that includes medical follow-up
(standard practices).
Preventing and Controlling
Hepatitis Virus Infections Among
Correctional Staff
Hepatitis A Virus Infection
• Hepatitis A is not occupationally acquired in the health-
care or correctional setting, and neither routine screening
nor routine vaccination of staff should be administered
(11). Not recommended.
Infection Control Plan for HBV
and HCV Prevention
• Measures to prevent occupational exposure to HBV and
HCV among correctional workers should be integrated
into each facility’s bloodborne pathogen and infection
control plan according to the requirements of the Occu-
pational Safety and Health Administration (OSHA) or
the respective state OSHA. Elements of this plan should
be coordinated with the infection control plan for correc-
tional workers for all other infectious agents (e.g., HIV
and Mycobacterium tuberculosis) (standard practice).
• The plan should cover all employees (including inmates
who are assigned work duties at a correctional facility)
who could be reasonably anticipated, as the result of job
duties, to be exposed to blood, bodily fluids, or other
materials that might contain HBV or HCV (standard prac-
tice).
• The plan should identify tasks, procedures, and job clas-
sifications in which occupational exposure to potentially
infectious material occurs — without regard to personal
protective clothing and equipment. The plan must be
accessible to employees and employee representatives. The
employer should review and update the plan at least
annually — more often if necessary to accommodate
changes or recommendations from appropriate agencies
(standard practice).
• The plan should mandate standard (i.e., universal) pre-
cautions for all contact with blood or body fluids. This
should include procedures used to prevent needle sticks,
including use of safer needle devices (139), to minimize
splashing and spraying of potentially infectious material,
and to ensure appropriate disinfection and decontamina-
tion of potentially contaminated surfaces and equipment,
and appropriate disinfection and disposal of infectious
material and contaminated clothing (198). As a part of
the plan, correctional facilities should require employees
to use appropriate personal protective equipment (e.g.,
gloves, gowns, masks, mouthpieces, and resuscitation bags)
that are provided by the employer (standard practice).
• The plan should ensure that all workers are familiar with
all aspects of infection control, including bloodborne
pathogens and their transmission, the written exposure
control plan, engineering and work practice controls, per-
sonal protective equipment, hepatitis B vaccine, response
to emergencies involving blood, how to handle exposure
incidents, the postexposure evaluation and follow-up pro-
gram, and signs/labels/color-coding to alert persons to
potentially infectious material (standard practice).
• Plan administrators should consider strategies to overcome
the unique barriers to an effective infection control plan
in a correctional environment (41). For example, poten-
tial inaccessibility of sharps disposal containers might
necessitate using specific safe-needle devices and other
strategies to minimize needle-stick injuries in correctional
health-care settings (standard practice).
• A work practices program should be established that
includes standard operating procedures for all activities
having exposure potential. No worker should engage in
such tasks or activities before receiving training pertain-
ing to the procedures, work practices, and protective equip-
ment required for that task (standard practice).
Preexposure Hepatitis B Vaccination
and Postexposure Management
for HBV and HCV
• Hepatitis B vaccination should be administered to all pre-
viously unvaccinated persons (e.g., correctional and medi-
cal staff ) whose work duties involve exposure to blood or
other potentially infectious body fluids (9,138,199).
Strongly recommended.
• Prevaccination serologic screening is not indicated for
persons being vaccinated because of occupational risk,
unless the hospital or health-care organization considers
screening cost-effective. Indicated.
• Staff with continued contact with patients or blood and
who are at ongoing risk for percutaneous injuries should
be tested for anti-HBs 1–2 months after completion of
the 3-dose vaccination series. Staff who do not respond to
a primary vaccine series should complete a second 3-dose
vaccine series or be evaluated to determine if they are
HBsAg-positive (47,199) (standard practice).
• For correctional workers who have no contact with
inmates and no routine exposure to blood and body flu-
ids in the correctional setting, timely postexposure pro-
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phylaxis should be provided if an exposure occurs, rather
than routine vaccination (47,199) (standard practice).
• Evaluation for appropriate postexposure prophylaxis for
an employee who has had an exposure incident should be
performed in a timely fashion according to recommenda-
tions for HBV and HCV (47). Strongly recommended.
• When an exposure to potentially infectious blood or body
fluid has occurred, a blood sample from the source per-
son should be tested for HBsAg and anti-HCV. If the
source person cannot be identified or tested, the respec-
tive postexposure protocol (i.e., HBV or HCV) should be
followed to evaluate the need for postexposure prophy-
laxis or follow-up (standard practice).
• Appropriate postexposure prophylaxis and follow-up for
HBV infection after exposure is dependent on the HBsAg
status of the source person, as well as the immunization
status of the exposed person (Tables 2 and 4) (47) (see
Recommendations for Adult Inmates) (standard practice).
• If the source person is anti-HCV positive, CDC guide-
lines for postexposure follow-up should be followed
(10,47) (see Recommendations for Adult Inmates) (stan-
dard practice).
HBV or HCV Serologic Testing
• Routine testing for HBV or HCV infection is not neces-
sary for correctional workers, except as described for hepa-




The unique nature of correctional institution populations
necessitates close collaboration with public health personnel
at state and local levels for effective implementation of the
recommendations in this report. Preventing and controlling
viral hepatitis among incarcerated and released persons, and
among persons in the communities to which they return,
requires defining specific roles for each agency.
• Correctional staff should review these recommenda-
tions and develop written policies for their implemen-
tation. Policies should include implementation by
contractors where correctional health care is provided
by the private sector. Correctional staff should also
monitor the 1) proportion of inmates (both adults and
juveniles) who begin and complete the hepatitis B
vaccine series; 2) prevalence of immunity to HBV
infection among incoming inmates; 3) vaccine-series–
completion rates for released prisoners; 4) proportion
of inmates tested for HCV infection and reasons that
inmates decline testing; and 5) prevalence of HCV
infection among incoming inmates.
• Correctional systems should establish close working
relationships with state and local health departments
to ensure awareness of viral hepatitis prevention and
control activities. Written agreements can better
ensure all agencies participate in 1) reporting and in-
vestigating acute cases of viral hepatitis among inmates;
2) reporting inmates with chronic HBV and HCV
infection in states where this is a requirement; 3) vac-
cination of contacts of inmates with chronic HBV
infection; and 4) follow-up of inmates released before
completing the hepatitis A or hepatitis B vaccine
series, or before completing treatment for chronic HBV
or HCV infection. Correctional staff should also col-
laborate with health department staff to provide hepa-
titis education and counseling to inmates and
correctional employees.
• Public health departments should work closely with
correctional systems to develop community-based strat-
egies for preventing and controlling viral hepatitis.
Integration of correctional health care into such strat-
egies can be facilitated through designation of health
department personnel to provide epidemiologic and
programmatic assistance to correctional facilities. Other
activities might include 1) development of record-keep-
ing systems that facilitate hepatitis B vaccination; 2)
case management of persons on antiviral therapy for
chronic hepatitis C or hepatitis B; 3) substance-abuse
treatment where appropriate; and 4) development of
training courses for correctional facility staff.
• Public health departments should be considered
resources for consultation on all aspects of viral hepa-
titis prevention and control, including quality assur-
ance of laboratory testing services. Training and
educational programs for correctional staff should
include topics such as diagnosis of viral hepatitis and
interpretation of laboratory test results, vaccination
delivery and assessment of vaccination programs, dis-
ease reporting, and health education. Health depart-
ment officials should provide educational information
to senior-level prison and jail officials and to county
and other elected officials.
• Public health departments should develop mechanisms
that encourage reporting of viral hepatitis cases identi-
fied in correctional facilities. In addition, mechanisms
should be established to provide epidemiologic con-
sultation for investigations of acute disease in the com-
plex setting of the correctional facility. Other areas for
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which mechanisms should be established include fol-
low-up of persons with chronic HBV and HCV infec-
tion for vaccination of contacts (HBV), and appropriate
counseling and referral for medical follow-up and treat-
ment.
Internet Resources
The following Internet sites provide additional information
(listed by source, topic, and website):
• CDC, viral hepatitis, http://www.cdc.gov/hepatitis.
• CDC, immunization, http://www.cdc.gov/nip.
• CDC, public health and IDUs, http://www.cdc.gov/idu.
• CDC, public health and corrections, http://www.nchstp.
cdc.gov/correctionalhealth.
• Immunization Action Coalition, immunization resources,
http://www.immunize.org.
• Immunization Action Coalition, model prevention pro-
grams, http//www.hepprograms.org.
• National Institutes of Health, National Institute of
Digestive Diseases (NIH, NIDDK), HCV treatment con-
sensus statement, http://consensus.nih.gov/cons/116/
116cdc_intro.htm.
• Federal Bureau of Prisons, treatment guidelines, http://
www.nicic.org/services/news/bop-medical.htm.
• National Commission on Correctional Health Care
(NCCHC), http://www.ncchc.org.
• American Correctional Association (ACA), http://
www.aca.org.
• National Institute of Justice (NIJ), Report on the Health
Status of Soon-To-Be-Released Inmates, http://
www.ncchc.org/pubs_stbr.html.
Published Resources
• CDC. Hepatitis B virus: a comprehensive strategy for
eliminating transmission in the United States through
universal childhood vaccination: recommendations of the
Immunization Practices Advisory Committee (ACIP).
MMWR 1991;40(No. RR-13):1–25.
• CDC. Recommendations for prevention and control of
hepatitis C virus (HCV) infection and HCV-related
chronic disease. MMWR 1998;47(No. RR-19):1–39.
• CDC. Prevention of hepatitis A through active or passive
immunization: recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP). MMWR
1999;48(No. RR-12):1–37.
• CDC. Updated U.S. Public Health Service guidelines for
the management of occupational exposures to HBV, HCV,
and HIV and recommendations for postexposure prophy-
laxis. MMWR 2001;50(No. RR-11):1–52.
• CDC. Immunization of adolescents: recommendations
of the Advisory Committee on Immunization Practices,
the American Academy of Pediatrics, the American Acad-
emy of Family Physicians, and the American Medical
Association. MMWR 1996;45(No. RR-13):1–16.
• CDC. General recommendations on immunization: rec-
ommendations of the Advisory Committee on Immuni-
zation Practices (ACIP) and the American Academy of
Family Physicians (AAFP). MMWR 2002;51(No. RR-
2):1–36.
• CDC. Recommendations of the Immunization Practices
Advisory Committee Prevention of Perinatal Transmis-
sion of Hepatitis B Virus: prenatal screening of all preg-
nant women for hepatitis B surface antigen. MMWR
1988;37:341–6.
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Appendix
Hepatitis A and B Vaccines
Hepatitis A Vaccine
Long-term protection from hepatitis A virus (HAV) infec-
tion can be achieved through active, preexposure vaccination
with hepatitis A vaccine. Inactivated hepatitis A vaccines
licensed for use in the United States are Havrix®
(GlaxoSmithKline Biologicals, Rixensart, Belgium), VAQTA®
(Merck & Co., Inc., Whitehouse Station, New Jersey), and
Twinrix® (GlaxoSmithKline Biologicals), a combined hepati-
tis A and hepatitis B vaccine (1,2). All are produced from HAV
grown in cell culture, inactivated with formalin, and formu-
lated with alum adjuvant in pediatric and adult dosages that
are 94%–100% effective in preventing clinical disease among
juveniles and adults when administered according to recom-
mended schedules (1,2) (Table 3).
Protective levels of antibody to HAV (anti-HAV) develop
among 94%–100% of vaccinated persons within 1 month
after administration of the first dose. A second dose results in
protective levels of antibody among all persons vaccinated,
and is considered necessary for long-term protection. Estimates
of antibody persistence suggest protective levels of anti-HAV
persist for >20 years (1).
A delay in administration of the second vaccine dose does
not result in lowered final antibody levels or seroconversion
rates, and restarting the vaccine series if the second dose is
delayed is not needed. Vaccination begun with vaccine from
one manufacturer can be completed with vaccine from the
other (3,4). Hepatitis A vaccine can be administered at the
same time as other vaccines, including hepatitis B vaccine,
without affecting immunogenicity or increasing the frequency
of adverse events.
Adverse Reactions
The most frequently reported adverse reactions occurring
<3 days after vaccination are soreness at the injection site (53%–
56%), headache (14–16%), and malaise (7%). Reviews of data
from multiple sources have not identified any serious adverse
events among juveniles or adults associated with hepatitis A
vaccination (1). Any adverse event occurring after hepatitis A
vaccination should be reported to the Vaccine Adverse Events
Reporting System (VAERS). Reporting forms can be obtained
by calling 1-800-822-7967.
Contraindications
Hepatitis A vaccine should not be administered to persons
with a history of hypersensitivity reactions to alum, or for
Havrix or Twinrix, to the preservative 2-phenoxyethanol. The
safety of hepatitis A vaccination during pregnancy has not been
determined. However, because this is an inactivated vaccine,
the theoretical risk to the developing fetus is low. The risk
associated with vaccination should be weighed against the risk
for hepatitis A among women who might be at high risk for
exposure to HAV infection. No special precautions are needed
when vaccinating immunocompromised persons.
Serologic Testing for HAV Infection
Antibody produced after HAV infection results in lifelong
immunity. Among adult populations with high rates of prior
HAV infection, prevaccination testing can reduce costs by
avoiding the vaccination of persons with prior immunity.
However, the vaccination of an immune person does not
increase the risk for adverse events. The decision to test should
be based on 1) expected prevalence of immunity; 2) cost of
vaccination compared with cost of serologic testing; and
3) likelihood that testing will not interfere with initiating vac-
cination.
Prevaccination testing of younger juveniles (ages <15 years)
is not indicated because of their low prevalence of infection.
Prevaccination testing is most likely to be cost-effective for
older juveniles and adults born in countries, or who have been
residents for extensive periods in countries, with a high ende-
micity of HAV infection (e.g., Mexico, South and Central
America, Africa, and all of Asia except Japan), populations
with historically high rates of infection (e.g., American Indi-
ans or Alaska Natives), and those engaging in behaviors that
place them at high risk for infection (e.g., drug users or men
who have sex with men). Because anti-HAV prevalence
increases with age, prevaccination testing of any person aged
>40 years would likely be cost-effective (1). Commercially
available tests for total anti-HAV can be used for prevaccination
testing. Postvaccination testing is not indicated because of high
rates of vaccine response among both adults and juveniles. In
addition, no Food and Drug Administration (FDA)-approved
testing method exists that has the sensitivity to detect low anti-
HAV concentrations after vaccination.
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Hepatitis B Vaccine
Vaccines available in the United States use hepatitis B sur-
face antigen (HBsAg) produced in yeast cells by recombinant
deoxyribonucleic acid (DNA) technology, and are formulated
to contain 5–40 µg HBsAg protein/mL and 0.5 mg/mL alu-
minum hydroxide as the adjuvant. The two available single
antigen hepatitis B vaccines are Recombivax HB® (Merck &
Co., Inc., Whitehouse Station, New Jersey) and Engerix-B®
(GlaxoSmithKline Biologicals, Rixensart, Belgium) (5). A com-
bination hepatitis A and hepatitis B vaccine, Twinrix, is also
licensed for persons aged >18 years old (2) (Table 4).
Antibody Response to Vaccination
Licensed formulations for both vaccines produce high
(>95%) rates of protective antibody (anti-HBs >10 mIU/mL)
when the complete series is administered in different sched-
ules to infants, juveniles, and adults aged <40 years (5). Among
healthy adults, 30%–50% develop a protective antibody
response after the first vaccine dose, 75% after the second dose,
and >95% after the third dose (5–9). Increasing the interval
between the first and second dose of vaccine has little effect
on immunogenicity or final antibody titer, although data are
limited regarding intervals >2 months among adults (5,8). The
third dose confers the maximum rate of seroprotection; it pri-
marily acts as a booster and confers optimal long-term protec-
tion through the induction of maximum immune memory
(5,9). Both licensed vaccines administered on a 0-, 1-, and
6-month schedule produce a >95% final seroprotection rate
among adolescents and healthy young adults, and studies
indicate that vaccination of adolescents and adults on a 0-, 2-
, and 4-month, and adolescents on a 0-,12-, and 24-month
schedule, achieved final seroprotection rates similar to the 0-,
1-, and 6-month schedule (8–10). In addition, a 2-dose vacci-
nation series using Recombivax HB® at the adult dosage has
been demonstrated among adolescents aged 11–15 years to
produce protective antibody responses equivalent to that of
the 3-dose series, although the long-term protection afforded
from this schedule is not known (8,11).
The duration of vaccine-induced antibody and protection
from hepatitis B virus (HBV) infection has been evaluated
among vaccinated infants, juveniles, and adults (5,12–14).
Studies indicate that although loss of detectable anti-HBs has
ranged from 13% to 60% by 9–15 years after vaccination,
immune memory provides protection from HBV infection,
and protection remains intact for >15 years, the longest
period for which follow-up data are available (5,12–14).
Because of the long duration of protection afforded by the
3-dose vaccine series, booster doses of vaccine are not needed
among vaccinated immunocompetent juveniles or adults.
Adverse Reactions
Adverse reactions associated with hepatitis B vaccine include
pain at the injection site (3%–29%) and a temperature >37.7ºC
(1%–6%), although these effects are reported no more fre-
quently among vaccine recipients than among placebo recipi-
ents in controlled trials (5). Anaphylaxis has been reported in
1/600,000 vaccine recipients; however, no deaths have been
attributed to vaccination. A number of case reports and case
series have claimed an association between hepatitis B vacci-
nation and serious adverse health events (e.g., multiple sclero-
sis) (15,16); however, these have not been proven by other
epidemiologic studies (17–22). Adverse events suspected to
be associated with hepatitis B vaccination should be reported
to VAERS, and reporting forms can be obtained by calling
1-800-822-7967.
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1. Which of the following are risk factors for viral hepatitis among
inmates?
A. Injection-drug use.
B. Sex among inmates and between inmates and staff.
C. Percutaneous exposures.
D. Occupational exposures.
E. All of the above.
F. None of the above.
2. Chronic hepatitis B virus (HBV) infection might result in . . .
A. an asymptomatic carrier state.
B. chronic persistent hepatitis.
C. chronic active hepatitis which progresses to cirrhosis.
D. chronic active hepatitis which progresses to liver cancer.
E. all of the above.
F. none of the above.
3. No association has been found with hepatitis C virus (HCV) infection
and military service or exposures resulting from medical, surgical, or




4. Routine HCV testing is recommended for . . .
A. persons who ever injected illegal drugs.
B. persons who received clotting factor concentrate produced before 1987.
C. persons ever on long-term hemodialysis.
D. persons with persistently abnormal alanine aminotransferase (ALT).
E. prior recipients of transfusions or organ transplants including those
who received blood or blood components or received an organ
transplant before July 1992.
F. all of the above.
5. A delay in the administration of the second hepatitis A vaccine dose
results in lowered final antibody levels or seroconversion, and if the
second dose is delayed, the series should be restarted.
A. True.
B. False.
6. Hepatitis B vaccination should be initiated even when completion of a
series cannot be ensured, because relatively high levels of immunity are
provided by one or two doses of vaccine. Administration of even a




7. To prevent false positives, screening for antibody to HCV should be
performed with enzyme immunoassay (EIA) testing as well as a more
specific assay (e.g., recombinant immunoblot assay [RIBA®]). These
tests detect >97% of anti-HCV, but do not distinguish among acute,




This MMWR provides information and recommendations regarding prevention and control of infections with hepatitis viruses in correctional settings. The
recommendations were prepared by CDC staff from the National Center for Infectious Diseases, in consultation with external consultants. The goal of this report
is to provide information and recommendations for physicians, health-care delivery staff, corrections staff, administrators, and other public health professionals who
deliver services to incarcerated persons. After completing this educational activity, the reader should be able to 1) identify the risk factors for transmission of viral
hepatitis among incarcerated persons; 2) describe the epidemiology of viral hepatitis in the United States; 3) describe the outcome of infection with hepatitis viruses;
4) describe methods used to prevent and control viral hepatitis in juvenile and adult correctional settings; and 5) identify infection control measures to prevent
occupational exposure to hepatitis B and C viruses among correctional workers.
To receive continuing education credit, please answer all of the following questions.
8. Which of the following drugs are currently FDA-approved for





9. Postexposure prophylaxis is necessary for a fully vaccinated juvenile
after a percutaneous or sexual exposure that might contain HBV.
A. True.
B. False.
10. Juveniles with chronic HBV or HCV infections, and their parents or
guardians, should be counseled regarding which of the following?
(Indicate all that apply.)
A. Preventing transmission to household, sexual, and drug-use contacts.
B. Referral for hepatitis B vaccination of susceptible contacts.
C. Ways to reduce further liver damage, including limiting alcohol and
drug use.
D. Postexposure prophylaxis.
11. Previously unvaccinated hepatitis B surface antigen-negative pregnant




12. CDC recommends that all persons who receive a medical evaluation in
a correctional facility be administered hepatitis B vaccine, unless they
have proof of completion of the vaccine series.
A. True.
B. False.
13. For which of the following persons is routine testing for HCV infection
recommended? (Indicate all that apply.)
A. Persons who have been tattooed.
B. Persons who have a history of sexually transmitted disease.
C. Persons who have ever injected illegal drugs.
D. Persons who have had a transfusion of blood or blood components
before July 1992.
E. Persons who have received clotting factor concentrates made before
1987.
14. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
















































































































15. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.




16. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.







18. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 but <4.0 hours.
D. >4.0 hours.
19. After reading this report, I am confident I can identify the risk factors
for transmission of viral hepatitis among incarcerated persons.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can describe the
epidemiology of viral hepatitis in the United States.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. After reading this report, I am confident I can describe the outcome of
infections with hepatitis viruses.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. After reading this report, I am confident I can describe methods used
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23. After reading this report, I am confident I can identify infection




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. The tables and boxes are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
27. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
28. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
29. How did you learn about this continuing education activity?
A. Internet.





Correct answers for questions 1–13.
1. E; 2. E; 3. A; 4. F; 5. B; 6. A; 7. A; 8. A, B, and C; 9. B; 10. A, B, and
C; 11. B; 12. A; 13. C, D, and E.
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